[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMAF896e_lDNvo2spEkcUuzQjxMNWJEMeYAjfiR64N6E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"Millennium Pharmaceuticals, Inc.",[4],178,false,0,19,20283,1,[13,16,19,22,24,27,30,33],{"name":14,"count":15},"Multiple Myeloma",24,{"name":17,"count":18},"Advanced Solid Tumors",14,{"name":20,"count":21},"Prostate Cancer",11,{"name":23,"count":21},"Healthy Volunteers",{"name":25,"count":26},"Lymphoma",8,{"name":28,"count":29},"Acute Myelogenous Leukemia",6,{"name":31,"count":32},"Advanced Nonhematologic Malignancies",5,{"name":34,"count":35},"Prostatic Neoplasms",4,[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,113,381,577,658,771,869,940,978,1016,1042,1074,1100,1123,1145,1163,1181,1207,1225,1243,1261,1290,1308,1326,1344,1362,1380,1398,1416,1529,1586,1649,1704,1755,1810,1850,1896,1922,1948,1981,2018,2044,2090,2123,2145,2176,2198,2234,2256,2289,2322,2359,2391,2413,2437,2455,2473,2500,2518,2536,2554,2577,2595,2620,2638,2656,2680,2705,2730,2755,2773,2791,2809,2830,2852,2870,2888,2942,2976,3033,3063,3093,3135,3168,3207,3229,3251,3287,3326,3355,3392,3410,3433,3451,3469,3487,3505,3528,3552,3570,3592,3616,3634,3659,3677,3701,3719,3737,3761,3779,3797,3815,3833,3851,3869,3887,3909,3936,3954,3972,3990,4008,4026,4044,4067,4090,4116,4134,4155,4173,4191,4215,4237,4259,4277,4295,4313,4331,4353,4388,4406,4424,4442,4460,4478,4496,4514,4532,4550,4568,4586,4608,4626,4644,4662,4685,4764,4794],{"intervention":46,"totalTrials":35,"cells":47},"Brentuximab Vedotin",{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":67,"PHASE3":82,"PHASE4":99,"NA":111},{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[52],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":64},"NCT01950364","A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma","COMPLETED",[39],"2014-10","2015-06","2013-11",20,[62,63],"Hodgkin Lymphoma","Anaplastic Large-cell Lymphoma",[65,66],"brentuximab vedotin","Brentuximab vedotin and rifampicin",{"trials":68,"activeCount":8},[69],{"nctId":70,"briefTitle":71,"status":55,"phases":72,"primaryCompletion":73,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":80},"NCT01492088","Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r\u002Fr) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma",[39,40],"2016-10-12","2018-04-12","2012-04-16",36,[78,79],"Relapsed or Refractory Hodgkin Lymphoma","Relapsed or Refractory Anaplastic Large-cell Lymphoma",[81],"Brentuximab vedotin",{"trials":83,"activeCount":8},[84],{"nctId":85,"briefTitle":86,"status":55,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":96},"NCT01578499","A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)",[41],"2016-05-31","2018-07-06","2012-06-11",131,[93,94,95],"Primary Cutaneous Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Cutaneous T-Cell Lymphoma",[46,97,98],"Methotrexate","Bexarotene",{"trials":100,"activeCount":8},[101],{"nctId":102,"briefTitle":103,"status":55,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"NCT01990534","A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma",[42],"2016-03-24","2020-03-12","2014-03-14",60,[62],[46],{"trials":112,"activeCount":8},[],{"intervention":114,"totalTrials":115,"cells":116},"Alisertib",21,{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":288,"PHASE3":361,"PHASE4":377,"NA":379},{"trials":118,"activeCount":8},[],{"trials":120,"activeCount":8},[121,134,144,154,166,180,189,200,212,223,232,243,265,275],{"nctId":122,"briefTitle":123,"status":55,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":131},"NCT01844583","Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",[39],"2014-08-04","2016-09-06","2013-06-25",55,[130,25],"Solid Tumors",[114,132,133],"Esomeprazole","Rifampin",{"nctId":135,"briefTitle":136,"status":55,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":143},"NCT01898078","Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas",[39],"2014-03-05","2017-01-24","2013-07-16",26,[17,25],[114],{"nctId":145,"briefTitle":146,"status":55,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":153},"NCT00962091","Study of MLN8237 in Participants With Advanced Solid Tumors",[39],"2011-12-28","2014-07-01","2009-09-25",53,[17],[114],{"nctId":155,"briefTitle":156,"status":55,"phases":157,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":164},"NCT01094288","A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen",[39],"2014-02-28","2017-01-04","2010-08-17",41,[17,163],"Adenocarcinoma of the Prostate",[114,165],"Docetaxel",{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT02551055","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma","TERMINATED",[39],"2017-02-17","2015-10-15",32,[175],"Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma",[177,178,114,179,165],"MLN1117","TAK-659","Paclitaxel",{"nctId":181,"briefTitle":182,"status":55,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":76,"conditions":186,"interventions":188},"NCT01512758","A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas",[39],"2013-10-08","2012-02-06",[17,187],"Lymphomas",[114],{"nctId":190,"briefTitle":191,"status":169,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":199},"NCT02367352","Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors",[39],"2017-05-23","2015-03-19",9,[17,197,198],"Ovarian Cancer","Small Cell Lung Cancer",[114,179],{"nctId":201,"briefTitle":202,"status":55,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT00651664","A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies",[39],"2010-09-01","2011-04-05","2007-10-22",59,[209],"Advanced Malignancies",[211],"alisertib",{"nctId":213,"briefTitle":214,"status":55,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":15,"conditions":219,"interventions":221},"NCT02259010","A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed\u002FRefractory Lymphoma",[39],"2015-03-27","2016-10-21","2014-10-22",[17,220],"Relapsed\u002FRefractory Lymphoma",[114,222],"Itraconazole",{"nctId":224,"briefTitle":225,"status":55,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":76,"conditions":230,"interventions":231},"NCT02214147","Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed\u002FRefractory Lymphoma With Varying Degrees of Hepatic Function",[39],"2016-04-05","2016-07-18","2014-08-21",[17,220],[114],{"nctId":233,"briefTitle":234,"status":55,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":241},"NCT01714947","Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib",[39],"2013-04-04","2013-06-14","2013-01-24",3,[17,25],[242,211],"[^14C]-alisertib",{"nctId":244,"briefTitle":245,"status":55,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":264},"NCT00697346","Study of MLN8237 in Participants With Advanced Hematological Malignancies",[39],"2016-10-01","2016-10-19","2008-07-11",58,[252,253,254,255,256,257,14,258,259,260,261,262,263],"B-cell Follicular Lymphoma","B-cell Marginal Zone Lymphoma","Diffuse Large B-cell Lymphoma","B-cell Mantle Cell Lymphoma","B-cell Small Lymphocytic Lymphoma","B-Cell Chronic Lymphocytic Leukemia","Waldenstrom's Macroglobulinemia","Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Anaplastic Large Cell Lymphoma","Enteropathy Associated T-cell Lymphoma","NK Lymphoma",[114],{"nctId":266,"briefTitle":267,"status":55,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":274},"NCT00500903","A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors",[39],"2010-08-01","2011-02-23","2007-05-15",87,[209],[114],{"nctId":276,"briefTitle":277,"status":55,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT02327169","A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies",[39],"2018-07-02","2015-01-14",81,[31],[284,285,114,179,286,287],"MLN2480","MLN0128","Cetuximab","Irinotecan",{"trials":289,"activeCount":8},[290,299,310,323,337,348],{"nctId":291,"briefTitle":292,"status":55,"phases":293,"primaryCompletion":294,"completion":295,"start":296,"enrollment":6,"conditions":297,"interventions":298},"NCT02038647","Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)",[40],"2016-01-03","2017-07-10","2014-05-12",[198],[114,179],{"nctId":300,"briefTitle":301,"status":55,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT00830518","A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome",[40],"2010-02-02","2011-07-04","2009-02-10",57,[28,308],"High-Grade Myelodysplastic Syndrome",[114],{"nctId":311,"briefTitle":312,"status":55,"phases":313,"primaryCompletion":314,"completion":315,"start":305,"enrollment":316,"conditions":317,"interventions":322},"NCT00807495","Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma",[40],"2011-01-04","2013-02-13",48,[254,318,319,320,321],"Mantle Cell Lymphoma","Burkitt's Lymphoma","T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma","Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component",[114],{"nctId":324,"briefTitle":325,"status":55,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":334},"NCT01397825","MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +\u002F- Vincristine",[39,40],"2015-02-05","2016-10-05","2011-08-09",45,[332,333,318,319],"Diffuse Large B-Cell Lymphoma","Transformed Follicular Lymphoma",[114,335,336],"Rituximab","Vincristine",{"nctId":338,"briefTitle":339,"status":55,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT00853307","MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma",[40],"2009-11-23","2011-01-27","2009-03-23",31,[346],"Ovarian Carcinoma",[114],{"nctId":349,"briefTitle":350,"status":55,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":360},"NCT01091428","Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer",[40],"2014-08-12","2017-07-19","2010-04-16",191,[346,357,358,359],"Fallopian Tube Cancer","Peritoneal Cancer","Breast Carcinoma",[114,179],{"trials":362,"activeCount":8},[363],{"nctId":364,"briefTitle":365,"status":55,"phases":366,"primaryCompletion":367,"completion":368,"start":90,"enrollment":369,"conditions":370,"interventions":373},"NCT01482962","Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed\u002FRefractory Peripheral T-Cell Lymphoma",[41],"2015-06-30","2017-12-18",271,[371,372],"Relapsed Peripheral T-Cell Lymphoma","Refractory Peripheral T-Cell Lymphoma",[114,374,375,376],"Pralatrexate","Gemcitabine","Romidepsin",{"trials":378,"activeCount":8},[],{"trials":380,"activeCount":8},[],{"intervention":382,"totalTrials":383,"cells":384},"Ixazomib",18,{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":476,"PHASE3":541,"PHASE4":573,"NA":575},{"trials":386,"activeCount":8},[],{"trials":388,"activeCount":8},[389,399,406,416,428,438,447,457,467],{"nctId":390,"briefTitle":391,"status":55,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":316,"conditions":395,"interventions":397},"NCT01912222","Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction",[39],"2015-03","2013-08",[17,396],"Hematologic Malignancies",[398],"IXAZOMIB",{"nctId":400,"briefTitle":401,"status":55,"phases":402,"primaryCompletion":57,"completion":57,"start":403,"enrollment":344,"conditions":404,"interventions":405},"NCT00893464","A Study of IXAZOMIB in Adult Patients With Lymphoma",[39],"2009-08",[25],[398],{"nctId":407,"briefTitle":408,"status":55,"phases":409,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT00830869","A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies",[39],"2012-04-20","2009-03-02",116,[414],"Advanced Non-hematologic Malignancies",[398],{"nctId":417,"briefTitle":418,"status":55,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT01645930","Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and\u002For Refractory Multiple Myeloma",[39],"2014-07-14","2017-04-11","2012-12-17",43,[14],[382,426,427],"Lenalidomide","Dexamethasone",{"nctId":429,"briefTitle":430,"status":431,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":8,"conditions":435,"interventions":437},"NCT03888534","Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)","WITHDRAWN",[39],"2022-08-30","2020-10-31",[436],"Precursor Cell Lymphoblastic Leukemia-lymphoma",[382],{"nctId":439,"briefTitle":440,"status":55,"phases":441,"primaryCompletion":442,"completion":443,"start":444,"enrollment":161,"conditions":445,"interventions":446},"NCT01830816","Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed\u002FRefractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment",[39],"2015-03-03","2016-11-18","2013-09-16",[14,17],[382],{"nctId":448,"briefTitle":449,"status":55,"phases":450,"primaryCompletion":451,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":456},"NCT01953783","Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB",[39],"2014-12-17","2016-02-09","2014-03-19",7,[17,25],[398],{"nctId":458,"briefTitle":459,"status":55,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT01318902","Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis",[39],"2018-11-13","2011-04-27",27,[465],"Light-Chain Amyloidosis",[382,427],{"nctId":468,"briefTitle":469,"status":55,"phases":470,"primaryCompletion":471,"completion":193,"start":472,"enrollment":108,"conditions":473,"interventions":475},"NCT00932698","Study of Oral Ixazomib in Adult Participants With Relapsed and\u002For Refractory (RR) Multiple Myeloma",[39],"2013-06-20","2009-10-12",[474],"Relapsed and Refractory Multiple Myeloma",[382],{"trials":477,"activeCount":8},[478,489,499,510,522,532],{"nctId":479,"briefTitle":480,"status":55,"phases":481,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":486},"NCT01335685","Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma",[39,40],"2016-12-29","2011-06-27",61,[14],[382,487,488],"Melphalan","Prednisone",{"nctId":490,"briefTitle":491,"status":55,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":498},"NCT01383928","Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma",[39,40],"2014-10-13","2017-11-27","2011-10-31",64,[14],[382,426,427],{"nctId":500,"briefTitle":501,"status":55,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT01939899","Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and\u002For Refractory Follicular Lymphoma",[40],"2016-06-01","2017-03-23","2013-10-31",29,[508],"Follicular Lymphoma",[398],{"nctId":511,"briefTitle":512,"status":55,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":520},"NCT03170882","A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma",[40],"2020-08-01","2021-11-26","2017-08-01",122,[519],"Relapsed and\u002For Refractory Multiple Myeloma",[382,521,427],"Pomalidomide",{"nctId":523,"briefTitle":524,"status":55,"phases":525,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":531},"NCT01217957","A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma",[39,40],"2013-03-08","2018-02-02","2010-11-22",65,[14],[382,426,427],{"nctId":533,"briefTitle":534,"status":55,"phases":535,"primaryCompletion":536,"completion":536,"start":138,"enrollment":537,"conditions":538,"interventions":539},"NCT02046070","Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and\u002For Refractory Multiple Myeloma",[40],"2018-06-29",148,[14],[540,382,427],"Cyclophosphamide",{"trials":542,"activeCount":8},[543,554,563],{"nctId":544,"briefTitle":545,"status":169,"phases":546,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT01659658","Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis",[41],"2022-07-11","2012-12-26",177,[551],"Relapsed or Refractory Systemic Light Chain Amyloidosis",[398,427,487,540,553,426],"Thalidomide",{"nctId":555,"briefTitle":556,"status":55,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT03748953","Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)",[41],"2023-12-06","2019-01-24",37,[14],[382],{"nctId":564,"briefTitle":565,"status":55,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT01850524","IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma",[41],"2019-12-02","2022-06-24","2013-04-29",705,[14],[382,427,426],{"trials":574,"activeCount":8},[],{"trials":576,"activeCount":8},[],{"intervention":427,"totalTrials":21,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":591,"PHASE3":634,"PHASE4":654,"NA":656},{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[583,587],{"nctId":417,"briefTitle":418,"status":55,"phases":584,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":585,"interventions":586},[39],[14],[382,426,427],{"nctId":458,"briefTitle":459,"status":55,"phases":588,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":589,"interventions":590},[39],[465],[382,427],{"trials":592,"activeCount":8},[593,604,608,612,626,630],{"nctId":594,"briefTitle":595,"status":55,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":602},"NCT03439280","A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed\u002FRefractory (r\u002Fr) Multiple Myeloma (MM)",[39,40],"2022-01-28","2018-04-20",50,[601,14],"Relapsed\u002FRefractory",[603,521,427],"Mezagitamab",{"nctId":490,"briefTitle":491,"status":55,"phases":605,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":606,"interventions":607},[39,40],[14],[382,426,427],{"nctId":511,"briefTitle":512,"status":55,"phases":609,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":610,"interventions":611},[40],[519],[382,521,427],{"nctId":613,"briefTitle":614,"status":55,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":621},"NCT00507442","Phase 1\u002F2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients",[39,40],"2010-10","2010-11","2007-08",158,[14],[622,623,624,625],"VELCADE","dexamethasone","cyclophosphamide","Revlimid",{"nctId":523,"briefTitle":524,"status":55,"phases":627,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":628,"interventions":629},[39,40],[14],[382,426,427],{"nctId":533,"briefTitle":534,"status":55,"phases":631,"primaryCompletion":536,"completion":536,"start":138,"enrollment":537,"conditions":632,"interventions":633},[40],[14],[540,382,427],{"trials":635,"activeCount":8},[636,640,650],{"nctId":544,"briefTitle":545,"status":169,"phases":637,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":638,"interventions":639},[41],[551],[398,427,487,540,553,426],{"nctId":641,"briefTitle":642,"status":55,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":648},"NCT00507416","Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",[41],"2013-03","2007-06",502,[14],[649,427,487,488,553],"Bortezomib",{"nctId":564,"briefTitle":565,"status":55,"phases":651,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":652,"interventions":653},[41],[14],[382,427,426],{"trials":655,"activeCount":8},[],{"trials":657,"activeCount":8},[],{"intervention":659,"totalTrials":195,"cells":660},"vedolizumab",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":693,"PHASE3":726,"PHASE4":767,"NA":769},{"trials":662,"activeCount":8},[],{"trials":664,"activeCount":8},[665,679],{"nctId":666,"briefTitle":667,"status":169,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":674},"NCT02723006","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",[39],"2018-05-11","2016-06-22",22,[673],"Melanoma",[675,676,659,677,678],"TAK-580","TAK-202","nivolumab","ipilimumab",{"nctId":680,"briefTitle":681,"status":55,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT01981616","Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab",[39],"2012-05","2012-07","2011-09",127,[688],"Inflammatory Bowel Disease",[690,691,692],"Vedolizumab","Hepatitis B vaccine","Oral cholera vaccine",{"trials":694,"activeCount":8},[695,706,716],{"nctId":696,"briefTitle":697,"status":55,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":705},"NCT01177228","Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis",[40],"2008-06","2008-09","2007-05",47,[704],"Ulcerative Colitis",[690],{"nctId":707,"briefTitle":708,"status":169,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":715},"NCT02993783","A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)",[40],"2018-05-09","2017-04-28",17,[714],"Allogeneic Hematopoietic Stem Cell Transplantation",[690],{"nctId":717,"briefTitle":718,"status":55,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT00619489","Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease",[40],"2010-03","2007-12",72,[704,724],"Crohn's Disease",[659],{"trials":727,"activeCount":8},[728,737,749,759],{"nctId":729,"briefTitle":730,"status":55,"phases":731,"primaryCompletion":732,"completion":733,"start":617,"enrollment":734,"conditions":735,"interventions":736},"NCT01224171","Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease",[41],"2012-02","2012-04",416,[724],[659],{"nctId":738,"briefTitle":739,"status":55,"phases":740,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":745,"interventions":747},"NCT03657160","Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation",[41],"2022-02-07","2022-05-09","2019-02-06",343,[746],"Hematopoietic Stem Cells",[748,690],"Vedolizumab Placebo",{"nctId":750,"briefTitle":751,"status":55,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":758},"NCT00783718","Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis",[41],"2011-12","2012-03","2009-01",895,[704],[659],{"nctId":760,"briefTitle":761,"status":55,"phases":762,"primaryCompletion":754,"completion":683,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT00783692","Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease",[41],"2008-12",1116,[724],[659],{"trials":768,"activeCount":8},[],{"trials":770,"activeCount":8},[],{"intervention":488,"totalTrials":195,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":839,"PHASE4":865,"NA":867},{"trials":774,"activeCount":8},[],{"trials":776,"activeCount":8},[],{"trials":778,"activeCount":8},[779,790,800,804,816,827],{"nctId":780,"briefTitle":781,"status":55,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":788},"NCT01040871","Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",[40],"2012-06","2012-08","2010-01",164,[332],[622,335,540,789,488,336],"Doxorubicin",{"nctId":791,"briefTitle":792,"status":55,"phases":793,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":799},"NCT00931918","Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients",[40],"2015-08","2009-10",206,[798],"Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)",[649,335,540,789,336,488],{"nctId":479,"briefTitle":480,"status":55,"phases":801,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":802,"interventions":803},[39,40],[14],[382,487,488],{"nctId":805,"briefTitle":806,"status":55,"phases":807,"primaryCompletion":808,"completion":809,"start":700,"enrollment":128,"conditions":810,"interventions":812},"NCT00715208","Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma",[40],"2011-02","2011-03",[811],"Relapsed Follicular Lymphoma",[813,624,814,622,815],"rituximab","doxorubicin","prednisone",{"nctId":817,"briefTitle":818,"status":55,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT01084655","Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer",[39,40],"2013-01","2016-03","2010-07",38,[20],[826,165,488],"TAK-700",{"nctId":828,"briefTitle":829,"status":55,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT01666314","Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer",[39,40],"2013-09-12","2016-09-01","2012-08-20",137,[20],[837,838,488],"Orteronel","Orteronel Placebo",{"trials":840,"activeCount":8},[841,851,855],{"nctId":842,"briefTitle":843,"status":55,"phases":844,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":850},"NCT01193244","Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",[41],"2014-01-01","2016-04-07","2010-10-01",1560,[20],[837,488],{"nctId":641,"briefTitle":642,"status":55,"phases":852,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":853,"interventions":854},[41],[14],[649,427,487,488,553],{"nctId":856,"briefTitle":857,"status":55,"phases":858,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":864},"NCT01193257","Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.",[41],"2013-05-16","2016-02-29","2010-11-15",1099,[20],[837,488,838],{"trials":866,"activeCount":8},[],{"trials":868,"activeCount":8},[],{"intervention":335,"totalTrials":26,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":886,"PHASE3":923,"PHASE4":936,"NA":938},{"trials":872,"activeCount":8},[],{"trials":874,"activeCount":8},[875],{"nctId":876,"briefTitle":877,"status":169,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":423,"conditions":881,"interventions":883},"NCT02954406","A Study of TAK-659 in Combination With Bendamustine (+\u002F-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",[39],"2020-07-27","2017-03-05",[882],"Lymphoma, Non-Hodgkin",[178,884,335,375,426,885],"Bendamustine","Ibrutinib",{"trials":887,"activeCount":8},[888,892,896,906,910,914],{"nctId":780,"briefTitle":781,"status":55,"phases":889,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":890,"interventions":891},[40],[332],[622,335,540,789,488,336],{"nctId":791,"briefTitle":792,"status":55,"phases":893,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":894,"interventions":895},[40],[798],[649,335,540,789,336,488],{"nctId":897,"briefTitle":898,"status":169,"phases":899,"primaryCompletion":685,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":904},"NCT00850499","Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab",[40],"2011-10","2009-09",12,[508],[905,813,622],"fludarabine",{"nctId":805,"briefTitle":806,"status":55,"phases":907,"primaryCompletion":808,"completion":809,"start":700,"enrollment":128,"conditions":908,"interventions":909},[40],[811],[813,624,814,622,815],{"nctId":324,"briefTitle":325,"status":55,"phases":911,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":912,"interventions":913},[39,40],[332,333,318,319],[114,335,336],{"nctId":915,"briefTitle":916,"status":55,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":922},"NCT00636792","A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma",[40],"2010-05","2008-02",73,[508],[622,884,335],{"trials":924,"activeCount":8},[925],{"nctId":926,"briefTitle":927,"status":55,"phases":928,"primaryCompletion":929,"completion":822,"start":930,"enrollment":931,"conditions":932,"interventions":934},"NCT00312845","Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",[41],"2010-06","2006-03",676,[933],"Non-Hodgkin's Lymphoma",[935,335],"Bortezomib + Rituximab",{"trials":937,"activeCount":8},[],{"trials":939,"activeCount":8},[],{"intervention":540,"totalTrials":29,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":968,"PHASE4":974,"NA":976},{"trials":943,"activeCount":8},[],{"trials":945,"activeCount":8},[],{"trials":947,"activeCount":8},[948,952,956,960,964],{"nctId":780,"briefTitle":781,"status":55,"phases":949,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":950,"interventions":951},[40],[332],[622,335,540,789,488,336],{"nctId":791,"briefTitle":792,"status":55,"phases":953,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":954,"interventions":955},[40],[798],[649,335,540,789,336,488],{"nctId":805,"briefTitle":806,"status":55,"phases":957,"primaryCompletion":808,"completion":809,"start":700,"enrollment":128,"conditions":958,"interventions":959},[40],[811],[813,624,814,622,815],{"nctId":613,"briefTitle":614,"status":55,"phases":961,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":962,"interventions":963},[39,40],[14],[622,623,624,625],{"nctId":533,"briefTitle":534,"status":55,"phases":965,"primaryCompletion":536,"completion":536,"start":138,"enrollment":537,"conditions":966,"interventions":967},[40],[14],[540,382,427],{"trials":969,"activeCount":8},[970],{"nctId":544,"briefTitle":545,"status":169,"phases":971,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":972,"interventions":973},[41],[551],[398,427,487,540,553,426],{"trials":975,"activeCount":8},[],{"trials":977,"activeCount":8},[],{"intervention":426,"totalTrials":29,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":992,"PHASE3":1002,"PHASE4":1012,"NA":1014},{"trials":981,"activeCount":8},[],{"trials":983,"activeCount":8},[984,988],{"nctId":876,"briefTitle":877,"status":169,"phases":985,"primaryCompletion":879,"completion":879,"start":880,"enrollment":423,"conditions":986,"interventions":987},[39],[882],[178,884,335,375,426,885],{"nctId":417,"briefTitle":418,"status":55,"phases":989,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":990,"interventions":991},[39],[14],[382,426,427],{"trials":993,"activeCount":8},[994,998],{"nctId":490,"briefTitle":491,"status":55,"phases":995,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":996,"interventions":997},[39,40],[14],[382,426,427],{"nctId":523,"briefTitle":524,"status":55,"phases":999,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":1000,"interventions":1001},[39,40],[14],[382,426,427],{"trials":1003,"activeCount":8},[1004,1008],{"nctId":544,"briefTitle":545,"status":169,"phases":1005,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":1006,"interventions":1007},[41],[551],[398,427,487,540,553,426],{"nctId":564,"briefTitle":565,"status":55,"phases":1009,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":1010,"interventions":1011},[41],[14],[382,427,426],{"trials":1013,"activeCount":8},[],{"trials":1015,"activeCount":8},[],{"intervention":487,"totalTrials":239,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1028,"PHASE4":1038,"NA":1040},{"trials":1019,"activeCount":8},[],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[1024],{"nctId":479,"briefTitle":480,"status":55,"phases":1025,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":1026,"interventions":1027},[39,40],[14],[382,487,488],{"trials":1029,"activeCount":8},[1030,1034],{"nctId":544,"briefTitle":545,"status":169,"phases":1031,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":1032,"interventions":1033},[41],[551],[398,427,487,540,553,426],{"nctId":641,"briefTitle":642,"status":55,"phases":1035,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":1036,"interventions":1037},[41],[14],[649,427,487,488,553],{"trials":1039,"activeCount":8},[],{"trials":1041,"activeCount":8},[],{"intervention":375,"totalTrials":239,"cells":1043},{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1062,"PHASE3":1064,"PHASE4":1070,"NA":1072},{"trials":1045,"activeCount":8},[],{"trials":1047,"activeCount":8},[1048,1052],{"nctId":876,"briefTitle":877,"status":169,"phases":1049,"primaryCompletion":879,"completion":879,"start":880,"enrollment":423,"conditions":1050,"interventions":1051},[39],[882],[178,884,335,375,426,885],{"nctId":1053,"briefTitle":1054,"status":55,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":496,"conditions":1058,"interventions":1059},"NCT01862328","Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors",[39],"2018-05-21","2013-06-10",[130],[1060,179,375,165,1061],"MLN4924","Carboplatin",{"trials":1063,"activeCount":8},[],{"trials":1065,"activeCount":8},[1066],{"nctId":364,"briefTitle":365,"status":55,"phases":1067,"primaryCompletion":367,"completion":368,"start":90,"enrollment":369,"conditions":1068,"interventions":1069},[41],[371,372],[114,374,375,376],{"trials":1071,"activeCount":8},[],{"trials":1073,"activeCount":8},[],{"intervention":837,"totalTrials":239,"cells":1075},{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1086,"PHASE4":1096,"NA":1098},{"trials":1077,"activeCount":8},[],{"trials":1079,"activeCount":8},[],{"trials":1081,"activeCount":8},[1082],{"nctId":828,"briefTitle":829,"status":55,"phases":1083,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":1084,"interventions":1085},[39,40],[20],[837,838,488],{"trials":1087,"activeCount":8},[1088,1092],{"nctId":842,"briefTitle":843,"status":55,"phases":1089,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":1090,"interventions":1091},[41],[20],[837,488],{"nctId":856,"briefTitle":857,"status":55,"phases":1093,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":1094,"interventions":1095},[41],[20],[837,488,838],{"trials":1097,"activeCount":8},[],{"trials":1099,"activeCount":8},[],{"intervention":553,"totalTrials":1101,"cells":1102},2,{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1107,"PHASE3":1109,"PHASE4":1119,"NA":1121},{"trials":1104,"activeCount":8},[],{"trials":1106,"activeCount":8},[],{"trials":1108,"activeCount":8},[],{"trials":1110,"activeCount":8},[1111,1115],{"nctId":544,"briefTitle":545,"status":169,"phases":1112,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":1113,"interventions":1114},[41],[551],[398,427,487,540,553,426],{"nctId":641,"briefTitle":642,"status":55,"phases":1116,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":1117,"interventions":1118},[41],[14],[649,427,487,488,553],{"trials":1120,"activeCount":8},[],{"trials":1122,"activeCount":8},[],{"intervention":838,"totalTrials":1101,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1135,"PHASE4":1141,"NA":1143},{"trials":1126,"activeCount":8},[],{"trials":1128,"activeCount":8},[],{"trials":1130,"activeCount":8},[1131],{"nctId":828,"briefTitle":829,"status":55,"phases":1132,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":1133,"interventions":1134},[39,40],[20],[837,838,488],{"trials":1136,"activeCount":8},[1137],{"nctId":856,"briefTitle":857,"status":55,"phases":1138,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":1139,"interventions":1140},[41],[20],[837,488,838],{"trials":1142,"activeCount":8},[],{"trials":1144,"activeCount":8},[],{"intervention":935,"totalTrials":11,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1153,"PHASE4":1159,"NA":1161},{"trials":1148,"activeCount":8},[],{"trials":1150,"activeCount":8},[],{"trials":1152,"activeCount":8},[],{"trials":1154,"activeCount":8},[1155],{"nctId":926,"briefTitle":927,"status":55,"phases":1156,"primaryCompletion":929,"completion":822,"start":930,"enrollment":931,"conditions":1157,"interventions":1158},[41],[933],[935,335],{"trials":1160,"activeCount":8},[],{"trials":1162,"activeCount":8},[],{"intervention":748,"totalTrials":11,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1177,"NA":1179},{"trials":1166,"activeCount":8},[],{"trials":1168,"activeCount":8},[],{"trials":1170,"activeCount":8},[],{"trials":1172,"activeCount":8},[1173],{"nctId":738,"briefTitle":739,"status":55,"phases":1174,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":1175,"interventions":1176},[41],[746],[748,690],{"trials":1178,"activeCount":8},[],{"trials":1180,"activeCount":8},[],{"intervention":1182,"totalTrials":11,"cells":1183},"VELCADE Administered by subcutaneous",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1203,"NA":1205},{"trials":1185,"activeCount":8},[],{"trials":1187,"activeCount":8},[],{"trials":1189,"activeCount":8},[],{"trials":1191,"activeCount":8},[1192],{"nctId":1193,"briefTitle":1194,"status":55,"phases":1195,"primaryCompletion":1196,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT00722566","A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma",[41],"2010-08","2010-09","2008-07",222,[14],[1182,1202],"VELCADE Administered by intravenous",{"trials":1204,"activeCount":8},[],{"trials":1206,"activeCount":8},[],{"intervention":1202,"totalTrials":11,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":8},[],{"trials":1212,"activeCount":8},[],{"trials":1214,"activeCount":8},[],{"trials":1216,"activeCount":8},[1217],{"nctId":1193,"briefTitle":1194,"status":55,"phases":1218,"primaryCompletion":1196,"completion":1197,"start":1198,"enrollment":1199,"conditions":1219,"interventions":1220},[41],[14],[1182,1202],{"trials":1222,"activeCount":8},[],{"trials":1224,"activeCount":8},[],{"intervention":374,"totalTrials":11,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":8},[],{"trials":1230,"activeCount":8},[],{"trials":1232,"activeCount":8},[],{"trials":1234,"activeCount":8},[1235],{"nctId":364,"briefTitle":365,"status":55,"phases":1236,"primaryCompletion":367,"completion":368,"start":90,"enrollment":369,"conditions":1237,"interventions":1238},[41],[371,372],[114,374,375,376],{"trials":1240,"activeCount":8},[],{"trials":1242,"activeCount":8},[],{"intervention":376,"totalTrials":11,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1257,"NA":1259},{"trials":1246,"activeCount":8},[],{"trials":1248,"activeCount":8},[],{"trials":1250,"activeCount":8},[],{"trials":1252,"activeCount":8},[1253],{"nctId":364,"briefTitle":365,"status":55,"phases":1254,"primaryCompletion":367,"completion":368,"start":90,"enrollment":369,"conditions":1255,"interventions":1256},[41],[371,372],[114,374,375,376],{"trials":1258,"activeCount":8},[],{"trials":1260,"activeCount":8},[],{"intervention":1262,"totalTrials":11,"cells":1263},"Rituximab 375 mg\u002Fm^2",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1286,"NA":1288},{"trials":1265,"activeCount":8},[],{"trials":1267,"activeCount":8},[],{"trials":1269,"activeCount":8},[],{"trials":1271,"activeCount":8},[1272],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1275,"primaryCompletion":845,"completion":1276,"start":1277,"enrollment":1278,"conditions":1279,"interventions":1280},"NCT00722137","Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",[41],"2017-06-17","2008-05-01",487,[318],[1262,1281,1282,1283,1284,1285],"Cyclophosphamide 750 mg\u002Fm^2","Doxorubicin 50 mg\u002Fm^2","VELCADE 1.3 mg\u002Fm^2","Prednisone 100 mg\u002Fm^2","Vincristine 1.4 mg\u002Fm^2",{"trials":1287,"activeCount":8},[],{"trials":1289,"activeCount":8},[],{"intervention":1281,"totalTrials":11,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1304,"NA":1306},{"trials":1293,"activeCount":8},[],{"trials":1295,"activeCount":8},[],{"trials":1297,"activeCount":8},[],{"trials":1299,"activeCount":8},[1300],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1301,"primaryCompletion":845,"completion":1276,"start":1277,"enrollment":1278,"conditions":1302,"interventions":1303},[41],[318],[1262,1281,1282,1283,1284,1285],{"trials":1305,"activeCount":8},[],{"trials":1307,"activeCount":8},[],{"intervention":1282,"totalTrials":11,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1322,"NA":1324},{"trials":1311,"activeCount":8},[],{"trials":1313,"activeCount":8},[],{"trials":1315,"activeCount":8},[],{"trials":1317,"activeCount":8},[1318],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1319,"primaryCompletion":845,"completion":1276,"start":1277,"enrollment":1278,"conditions":1320,"interventions":1321},[41],[318],[1262,1281,1282,1283,1284,1285],{"trials":1323,"activeCount":8},[],{"trials":1325,"activeCount":8},[],{"intervention":1283,"totalTrials":11,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":8},[],{"trials":1331,"activeCount":8},[],{"trials":1333,"activeCount":8},[],{"trials":1335,"activeCount":8},[1336],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1337,"primaryCompletion":845,"completion":1276,"start":1277,"enrollment":1278,"conditions":1338,"interventions":1339},[41],[318],[1262,1281,1282,1283,1284,1285],{"trials":1341,"activeCount":8},[],{"trials":1343,"activeCount":8},[],{"intervention":1284,"totalTrials":11,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1358,"NA":1360},{"trials":1347,"activeCount":8},[],{"trials":1349,"activeCount":8},[],{"trials":1351,"activeCount":8},[],{"trials":1353,"activeCount":8},[1354],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1355,"primaryCompletion":845,"completion":1276,"start":1277,"enrollment":1278,"conditions":1356,"interventions":1357},[41],[318],[1262,1281,1282,1283,1284,1285],{"trials":1359,"activeCount":8},[],{"trials":1361,"activeCount":8},[],{"intervention":1285,"totalTrials":11,"cells":1363},{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1376,"NA":1378},{"trials":1365,"activeCount":8},[],{"trials":1367,"activeCount":8},[],{"trials":1369,"activeCount":8},[],{"trials":1371,"activeCount":8},[1372],{"nctId":1273,"briefTitle":1274,"status":55,"phases":1373,"primaryCompletion":845,"completion":1276,"start":1277,"enrollment":1278,"conditions":1374,"interventions":1375},[41],[318],[1262,1281,1282,1283,1284,1285],{"trials":1377,"activeCount":8},[],{"trials":1379,"activeCount":8},[],{"intervention":97,"totalTrials":11,"cells":1381},{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1388,"PHASE4":1394,"NA":1396},{"trials":1383,"activeCount":8},[],{"trials":1385,"activeCount":8},[],{"trials":1387,"activeCount":8},[],{"trials":1389,"activeCount":8},[1390],{"nctId":85,"briefTitle":86,"status":55,"phases":1391,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":1392,"interventions":1393},[41],[93,94,95],[46,97,98],{"trials":1395,"activeCount":8},[],{"trials":1397,"activeCount":8},[],{"intervention":98,"totalTrials":11,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1412,"NA":1414},{"trials":1401,"activeCount":8},[],{"trials":1403,"activeCount":8},[],{"trials":1405,"activeCount":8},[],{"trials":1407,"activeCount":8},[1408],{"nctId":85,"briefTitle":86,"status":55,"phases":1409,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":1410,"interventions":1411},[41],[93,94,95],[46,97,98],{"trials":1413,"activeCount":8},[],{"trials":1415,"activeCount":8},[],{"intervention":179,"totalTrials":1417,"cells":1418},13,{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1502,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1420,"activeCount":8},[],{"trials":1422,"activeCount":8},[1423,1433,1437,1447,1459,1463,1467,1479,1489,1498],{"nctId":1424,"briefTitle":1425,"status":55,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1431},"NCT02122770","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors",[39],"2017-06-05","2014-04-01",51,[17],[1060,1432,222,165,1061,179],"Fluconazole",{"nctId":1053,"briefTitle":1054,"status":55,"phases":1434,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":496,"conditions":1435,"interventions":1436},[39],[130],[1060,179,375,165,1061],{"nctId":1438,"briefTitle":1439,"status":55,"phases":1440,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":484,"conditions":1443,"interventions":1445},"NCT02412722","A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",[39],"2018-05-31","2015-03-26",[1444],"Non-hematologic Malignancy",[1446,179],"Sapanisertib",{"nctId":1448,"briefTitle":1449,"status":55,"phases":1450,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT01351350","Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With\u002FWithout Trastuzumab, in Subjects With Advanced Solid Malignancies",[39],"2017-09-15","2011-02-28",68,[1455,396],"Advanced Solid Malignancies",[285,1457,1458],"paclitaxel","trastuzumab",{"nctId":167,"briefTitle":168,"status":169,"phases":1460,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":1461,"interventions":1462},[39],[175],[177,178,114,179,165],{"nctId":190,"briefTitle":191,"status":169,"phases":1464,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":1465,"interventions":1466},[39],[17,197,198],[114,179],{"nctId":1468,"briefTitle":1469,"status":55,"phases":1470,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":26,"conditions":1474,"interventions":1476},"NCT03057366","A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors",[39],"2018-02-08","2018-11-05","2017-05-11",[1475],"Advanced Solid Tumors, Neoplasms, Advanced Solid",[1477,1478,165,1061,179],"Pevonedistat","[14C]-Pevonedistat",{"nctId":1480,"briefTitle":1481,"status":55,"phases":1482,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":60,"conditions":1486,"interventions":1488},"NCT03486314","A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors",[39],"2019-05-10","2021-02-28","2018-08-13",[1487],"Advanced Solid Neoplasm",[1477,133,165,1061,179],{"nctId":1490,"briefTitle":1491,"status":55,"phases":1492,"primaryCompletion":1493,"completion":1494,"start":1495,"enrollment":1453,"conditions":1496,"interventions":1497},"NCT03330106","A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors",[39],"2019-01-07","2021-06-21","2017-11-15",[1487],[1477,165,1061,179],{"nctId":276,"briefTitle":277,"status":55,"phases":1499,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":1500,"interventions":1501},[39],[31],[284,285,114,179,286,287],{"trials":1503,"activeCount":8},[1504,1508,1519],{"nctId":291,"briefTitle":292,"status":55,"phases":1505,"primaryCompletion":294,"completion":295,"start":296,"enrollment":6,"conditions":1506,"interventions":1507},[40],[198],[114,179],{"nctId":1509,"briefTitle":1510,"status":55,"phases":1511,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":1516,"interventions":1518},"NCT02725268","A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer",[40],"2019-07-02","2020-10-30","2016-04-01",241,[1517],"Endometrial Neoplasms",[179,1446,177],{"nctId":349,"briefTitle":350,"status":55,"phases":1520,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":1521,"interventions":1522},[40],[346,357,358,359],[114,179],{"trials":1524,"activeCount":8},[],{"trials":1526,"activeCount":8},[],{"trials":1528,"activeCount":8},[],{"intervention":165,"totalTrials":195,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1563,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1532,"activeCount":8},[],{"trials":1534,"activeCount":8},[1535,1539,1543,1547,1551,1555,1559],{"nctId":1424,"briefTitle":1425,"status":55,"phases":1536,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":1537,"interventions":1538},[39],[17],[1060,1432,222,165,1061,179],{"nctId":1053,"briefTitle":1054,"status":55,"phases":1540,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":496,"conditions":1541,"interventions":1542},[39],[130],[1060,179,375,165,1061],{"nctId":155,"briefTitle":156,"status":55,"phases":1544,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":1545,"interventions":1546},[39],[17,163],[114,165],{"nctId":167,"briefTitle":168,"status":169,"phases":1548,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":1549,"interventions":1550},[39],[175],[177,178,114,179,165],{"nctId":1468,"briefTitle":1469,"status":55,"phases":1552,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":26,"conditions":1553,"interventions":1554},[39],[1475],[1477,1478,165,1061,179],{"nctId":1480,"briefTitle":1481,"status":55,"phases":1556,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":60,"conditions":1557,"interventions":1558},[39],[1487],[1477,133,165,1061,179],{"nctId":1490,"briefTitle":1491,"status":55,"phases":1560,"primaryCompletion":1493,"completion":1494,"start":1495,"enrollment":1453,"conditions":1561,"interventions":1562},[39],[1487],[1477,165,1061,179],{"trials":1564,"activeCount":8},[1565,1576],{"nctId":1566,"briefTitle":1567,"status":169,"phases":1568,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":18,"conditions":1572,"interventions":1574},"NCT02393209","Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer",[39,40],"2017-01-12","2017-01-20","2015-06-03",[1573],"Non-small Cell Lung Cancer",[165,1575],"TAK-117",{"nctId":817,"briefTitle":818,"status":55,"phases":1577,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":1578,"interventions":1579},[39,40],[20],[826,165,488],{"trials":1581,"activeCount":8},[],{"trials":1583,"activeCount":8},[],{"trials":1585,"activeCount":8},[],{"intervention":622,"totalTrials":26,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1589,"activeCount":8},[],{"trials":1591,"activeCount":8},[],{"trials":1593,"activeCount":8},[1594,1604,1608,1612,1621,1625,1629,1633],{"nctId":1595,"briefTitle":1596,"status":55,"phases":1597,"primaryCompletion":1598,"completion":901,"start":1599,"enrollment":1600,"conditions":1601,"interventions":1603},"NCT00298766","Open-Label Phase 1\u002F2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis",[39,40],"2009-07","2005-06",70,[1602],"Amyloidosis",[622],{"nctId":780,"briefTitle":781,"status":55,"phases":1605,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":1606,"interventions":1607},[40],[332],[622,335,540,789,488,336],{"nctId":897,"briefTitle":898,"status":169,"phases":1609,"primaryCompletion":685,"completion":900,"start":901,"enrollment":902,"conditions":1610,"interventions":1611},[40],[508],[905,813,622],{"nctId":1613,"briefTitle":1614,"status":55,"phases":1615,"primaryCompletion":1616,"conditions":1617,"interventions":1619},"NCT00343720","Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy",[40],"2007-10",[1618],"Non-Small Cell Lung Cancer",[622,1620],"Alimta",{"nctId":805,"briefTitle":806,"status":55,"phases":1622,"primaryCompletion":808,"completion":809,"start":700,"enrollment":128,"conditions":1623,"interventions":1624},[40],[811],[813,624,814,622,815],{"nctId":915,"briefTitle":916,"status":55,"phases":1626,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":1627,"interventions":1628},[40],[508],[622,884,335],{"nctId":613,"briefTitle":614,"status":55,"phases":1630,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":1631,"interventions":1632},[39,40],[14],[622,623,624,625],{"nctId":1634,"briefTitle":1635,"status":169,"phases":1636,"primaryCompletion":645,"completion":1637,"start":1638,"conditions":1639,"interventions":1642},"NCT00117351","VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features",[40],"2007-07","2005-04",[1640,1641],"Carcinoma, Non-Small-Cell Lung","Adenocarcinoma, Bronchiolo-Alveolar",[622],{"trials":1644,"activeCount":8},[],{"trials":1646,"activeCount":8},[],{"trials":1648,"activeCount":8},[],{"intervention":285,"totalTrials":32,"cells":1650},{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1684,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1652,"activeCount":8},[],{"trials":1654,"activeCount":8},[1655,1664,1668,1680],{"nctId":1656,"briefTitle":1657,"status":55,"phases":1658,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT01058707","Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies",[39],"2019-02-07","2010-01-04",198,[1455],[285],{"nctId":1448,"briefTitle":1449,"status":55,"phases":1665,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":1453,"conditions":1666,"interventions":1667},[39],[1455,396],[285,1457,1458],{"nctId":1669,"briefTitle":1670,"status":55,"phases":1671,"primaryCompletion":1672,"completion":1673,"start":617,"enrollment":1674,"conditions":1675,"interventions":1679},"NCT01118689","Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia",[39],"2013-05","2013-07",39,[1676,1677,1678],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","Waldenstrom Macroglobulinemia",[285],{"nctId":276,"briefTitle":277,"status":55,"phases":1681,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":1682,"interventions":1683},[39],[31],[284,285,114,179,286,287],{"trials":1685,"activeCount":8},[1686],{"nctId":1687,"briefTitle":1688,"status":55,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":1693,"conditions":1694,"interventions":1696},"NCT02724020","MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma",[40],"2020-02-03","2020-10-13","2016-06-30",96,[1695],"Clear-cell Metastatic Renal Cell Carcinoma",[1697,285,177],"Everolimus",{"trials":1699,"activeCount":8},[],{"trials":1701,"activeCount":8},[],{"trials":1703,"activeCount":8},[],{"intervention":1575,"totalTrials":35,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1743,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1707,"activeCount":8},[],{"trials":1709,"activeCount":8},[1710,1721,1733],{"nctId":1711,"briefTitle":1712,"status":55,"phases":1713,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":1717,"conditions":1718,"interventions":1719},"NCT01899053","A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies",[39],"2017-01-31","2018-04-30","2013-06-28",101,[31],[1720,1575],"TAK-228",{"nctId":1722,"briefTitle":1723,"status":55,"phases":1724,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1731},"NCT02625259","A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants",[39],"2016-05-16","2016-07-22","2016-01-08",54,[1730],"Neoplasm, Advanced or Metastatic",[1575,1732,1575],"Lansoprazole",{"nctId":1734,"briefTitle":1735,"status":55,"phases":1736,"primaryCompletion":1737,"completion":1738,"start":900,"enrollment":1739,"conditions":1740,"interventions":1742},"NCT01449370","Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer",[39],"2015-07","2016-01",125,[1741],"Metastatic Solid Tumors",[1575],{"trials":1744,"activeCount":8},[1745],{"nctId":1566,"briefTitle":1567,"status":169,"phases":1746,"primaryCompletion":1569,"completion":1570,"start":1571,"enrollment":18,"conditions":1747,"interventions":1748},[39,40],[1573],[165,1575],{"trials":1750,"activeCount":8},[],{"trials":1752,"activeCount":8},[],{"trials":1754,"activeCount":8},[],{"intervention":1756,"totalTrials":35,"cells":1757},"MLN0264",{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1785,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1759,"activeCount":8},[],{"trials":1761,"activeCount":8},[1762,1770],{"nctId":1763,"briefTitle":1764,"status":55,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":783,"enrollment":161,"conditions":1767,"interventions":1769},"NCT01577758","Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C",[39],"2014-02",[1768],"Advanced Gastrointestinal Malignancies",[1756],{"nctId":1771,"briefTitle":1772,"status":169,"phases":1773,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":902,"conditions":1776,"interventions":1784},"NCT02391038","MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C",[39],"2015-10","2014-12",[1777,1778,1779,1780,1781,1782,1783],"Advanced Gastrointestinal Carcinoma","Gastroesophageal Junction Adenocarcinoma","Recurrent Gastric Adenocarcinoma","Recurrent Gastroesophageal Junction Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Recurrent Gastrointestinal Carcinoma",[1756],{"trials":1786,"activeCount":8},[1787,1796],{"nctId":1788,"briefTitle":1789,"status":169,"phases":1790,"primaryCompletion":1791,"completion":1791,"start":125,"enrollment":823,"conditions":1792,"interventions":1795},"NCT02202759","A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction",[40],"2016-01-15",[1793,1794],"Adenocarcinoma of the Stomach","Gastroesophageal Junction Expressing Guanylyl Cyclase C",[1756],{"nctId":1797,"briefTitle":1798,"status":169,"phases":1799,"primaryCompletion":1791,"completion":1791,"start":1800,"enrollment":423,"conditions":1801,"interventions":1803},"NCT02202785","A Study of MLN0264 in Patients With Pancreatic Cancer",[40],"2014-07-02",[1802],"Pancreatic Adenocarcinoma",[1756],{"trials":1805,"activeCount":8},[],{"trials":1807,"activeCount":8},[],{"trials":1809,"activeCount":8},[],{"intervention":1477,"totalTrials":35,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1828,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1813,"activeCount":8},[],{"trials":1815,"activeCount":8},[1816,1820,1824],{"nctId":1468,"briefTitle":1469,"status":55,"phases":1817,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":26,"conditions":1818,"interventions":1819},[39],[1475],[1477,1478,165,1061,179],{"nctId":1480,"briefTitle":1481,"status":55,"phases":1821,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":60,"conditions":1822,"interventions":1823},[39],[1487],[1477,133,165,1061,179],{"nctId":1490,"briefTitle":1491,"status":55,"phases":1825,"primaryCompletion":1493,"completion":1494,"start":1495,"enrollment":1453,"conditions":1826,"interventions":1827},[39],[1487],[1477,165,1061,179],{"trials":1829,"activeCount":8},[1830],{"nctId":1831,"briefTitle":1832,"status":55,"phases":1833,"primaryCompletion":1834,"completion":1835,"start":1836,"enrollment":1837,"conditions":1838,"interventions":1842},"NCT02610777","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",[40],"2019-09-04","2021-07-23","2016-04-14",120,[1839,1840,1841],"Myelodysplastic Syndromes","Leukemia, Myelomonocytic, Chronic","Leukemia, Myeloid, Acute",[1843,1477],"Azacitidine",{"trials":1845,"activeCount":8},[],{"trials":1847,"activeCount":8},[],{"trials":1849,"activeCount":8},[],{"intervention":1851,"totalTrials":239,"cells":1852},"TAK-906 Maleate",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1865,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1854,"activeCount":8},[],{"trials":1856,"activeCount":8},[1857],{"nctId":1858,"briefTitle":1859,"status":55,"phases":1860,"primaryCompletion":1861,"completion":295,"start":1427,"enrollment":902,"conditions":1862,"interventions":1864},"NCT03161405","A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants",[39],"2017-07-02",[1863],"Healthy Participants",[1851,222],{"trials":1866,"activeCount":8},[1867,1878],{"nctId":1868,"briefTitle":1869,"status":55,"phases":1870,"primaryCompletion":1871,"completion":1871,"start":1872,"enrollment":1429,"conditions":1873,"interventions":1875},"NCT03268941","A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)",[40],"2018-03-09","2017-09-26",[1874],"Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis",[1851,1876,1877],"Metaclopramide","TAK-906 Maleate Placebo",{"nctId":1879,"briefTitle":1880,"status":55,"phases":1881,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1889},"NCT03544229","A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis",[40],"2021-06-14","2021-07-15","2018-10-14",242,[1887,1888],"Diabetic Gastroparesis","Idiopathic Gastroparesis",[1851],{"trials":1891,"activeCount":8},[],{"trials":1893,"activeCount":8},[],{"trials":1895,"activeCount":8},[],{"intervention":789,"totalTrials":239,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1899,"activeCount":8},[],{"trials":1901,"activeCount":8},[],{"trials":1903,"activeCount":8},[1904,1908,1912],{"nctId":780,"briefTitle":781,"status":55,"phases":1905,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":1906,"interventions":1907},[40],[332],[622,335,540,789,488,336],{"nctId":791,"briefTitle":792,"status":55,"phases":1909,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":1910,"interventions":1911},[40],[798],[649,335,540,789,336,488],{"nctId":805,"briefTitle":806,"status":55,"phases":1913,"primaryCompletion":808,"completion":809,"start":700,"enrollment":128,"conditions":1914,"interventions":1915},[40],[811],[813,624,814,622,815],{"trials":1917,"activeCount":8},[],{"trials":1919,"activeCount":8},[],{"trials":1921,"activeCount":8},[],{"intervention":336,"totalTrials":239,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1925,"activeCount":8},[],{"trials":1927,"activeCount":8},[],{"trials":1929,"activeCount":8},[1930,1934,1938],{"nctId":780,"briefTitle":781,"status":55,"phases":1931,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":1932,"interventions":1933},[40],[332],[622,335,540,789,488,336],{"nctId":791,"briefTitle":792,"status":55,"phases":1935,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":1936,"interventions":1937},[40],[798],[649,335,540,789,336,488],{"nctId":324,"briefTitle":325,"status":55,"phases":1939,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":1940,"interventions":1941},[39,40],[332,333,318,319],[114,335,336],{"trials":1943,"activeCount":8},[],{"trials":1945,"activeCount":8},[],{"trials":1947,"activeCount":8},[],{"intervention":826,"totalTrials":239,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1951,"activeCount":8},[],{"trials":1953,"activeCount":8},[],{"trials":1955,"activeCount":8},[1956,1965,1971],{"nctId":1957,"briefTitle":1958,"status":55,"phases":1959,"primaryCompletion":820,"completion":1960,"start":1961,"enrollment":1962,"conditions":1963,"interventions":1964},"NCT00569153","Safety Study of TAK-700 in Subjects With Prostate Cancer.",[39,40],"2013-02","2008-04",123,[34],[826],{"nctId":1966,"briefTitle":1967,"status":55,"phases":1968,"primaryCompletion":820,"completion":644,"start":918,"enrollment":823,"conditions":1969,"interventions":1970},"NCT01046916","Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen",[40],[20],[826],{"nctId":817,"briefTitle":818,"status":55,"phases":1972,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":1973,"interventions":1974},[39,40],[20],[826,165,488],{"trials":1976,"activeCount":8},[],{"trials":1978,"activeCount":8},[],{"trials":1980,"activeCount":8},[],{"intervention":1843,"totalTrials":239,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":2006,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":1984,"activeCount":8},[],{"trials":1986,"activeCount":8},[1987,1997],{"nctId":1988,"briefTitle":1989,"status":55,"phases":1990,"primaryCompletion":394,"completion":1991,"start":1992,"enrollment":722,"conditions":1993,"interventions":1996},"NCT00911066","MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia",[39],"2013-10","2009-06",[28,1994,1995],"Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome",[1060,1843],{"nctId":1998,"briefTitle":1999,"status":55,"phases":2000,"primaryCompletion":2001,"completion":2002,"start":2003,"enrollment":496,"conditions":2004,"interventions":2005},"NCT01814826","Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older",[39],"2016-05-03","2018-04-08","2013-04-10",[28],[1060,1843],{"trials":2007,"activeCount":8},[2008],{"nctId":1831,"briefTitle":1832,"status":55,"phases":2009,"primaryCompletion":1834,"completion":1835,"start":1836,"enrollment":1837,"conditions":2010,"interventions":2011},[40],[1839,1840,1841],[1843,1477],{"trials":2013,"activeCount":8},[],{"trials":2015,"activeCount":8},[],{"trials":2017,"activeCount":8},[],{"intervention":177,"totalTrials":239,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2028,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2021,"activeCount":8},[],{"trials":2023,"activeCount":8},[2024],{"nctId":167,"briefTitle":168,"status":169,"phases":2025,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":2026,"interventions":2027},[39],[175],[177,178,114,179,165],{"trials":2029,"activeCount":8},[2030,2034],{"nctId":1509,"briefTitle":1510,"status":55,"phases":2031,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":2032,"interventions":2033},[40],[1517],[179,1446,177],{"nctId":1687,"briefTitle":1688,"status":55,"phases":2035,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":1693,"conditions":2036,"interventions":2037},[40],[1695],[1697,285,177],{"trials":2039,"activeCount":8},[],{"trials":2041,"activeCount":8},[],{"trials":2043,"activeCount":8},[],{"intervention":2045,"totalTrials":239,"cells":2046},"TAK-931",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2070,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2048,"activeCount":8},[],{"trials":2050,"activeCount":8},[2051,2060],{"nctId":2052,"briefTitle":2053,"status":55,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":105,"enrollment":2056,"conditions":2057,"interventions":2059},"NCT02699749","A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors",[39],"2019-12-21",80,[2058],"Nonhematologic Neoplasms, Advanced",[2045],{"nctId":2061,"briefTitle":2062,"status":55,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":60,"conditions":2066,"interventions":2068},"NCT03708211","A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors",[39],"2019-12-03","2019-03-28",[2067],"Neoplasms, Advanced Solid",[2069,2045,132],"TAK-931 PIC",{"trials":2071,"activeCount":8},[2072],{"nctId":2073,"briefTitle":2074,"status":55,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":1717,"conditions":2078,"interventions":2083},"NCT03261947","A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors",[40],"2020-08-24","2017-10-25",[2079,2080,2081,2082],"Metastatic Pancreatic Cancer","Colorectal Cancer","Esophageal Neoplasms","Carcinoma, Non-small-cell Lung",[2045],{"trials":2085,"activeCount":8},[],{"trials":2087,"activeCount":8},[],{"trials":2089,"activeCount":8},[],{"intervention":2091,"totalTrials":1101,"cells":2092},"VELCADE TM (bortezomib) for",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2094,"activeCount":8},[],{"trials":2096,"activeCount":8},[],{"trials":2098,"activeCount":8},[2099,2108],{"nctId":2100,"briefTitle":2101,"status":55,"phases":2102,"primaryCompletion":2103,"start":2104,"enrollment":2105,"conditions":2106,"interventions":2107},"NCT00064610","Phase I\u002FII Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer",[39,40],"2004-12","2002-12",102,[34],[2091],{"nctId":2109,"briefTitle":2110,"status":55,"phases":2111,"primaryCompletion":2112,"start":2113,"enrollment":2114,"conditions":2115,"interventions":2116},"NCT00063713","VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",[40],"2005-12","2003-06",152,[318],[2091],{"trials":2118,"activeCount":8},[],{"trials":2120,"activeCount":8},[],{"trials":2122,"activeCount":8},[],{"intervention":884,"totalTrials":1101,"cells":2124},{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2133,"PHASE3":2139,"PHASE4":2141,"NA":2143},{"trials":2126,"activeCount":8},[],{"trials":2128,"activeCount":8},[2129],{"nctId":876,"briefTitle":877,"status":169,"phases":2130,"primaryCompletion":879,"completion":879,"start":880,"enrollment":423,"conditions":2131,"interventions":2132},[39],[882],[178,884,335,375,426,885],{"trials":2134,"activeCount":8},[2135],{"nctId":915,"briefTitle":916,"status":55,"phases":2136,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":2137,"interventions":2138},[40],[508],[622,884,335],{"trials":2140,"activeCount":8},[],{"trials":2142,"activeCount":8},[],{"trials":2144,"activeCount":8},[],{"intervention":2146,"totalTrials":1101,"cells":2147},"MLN2704",{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2159,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2149,"activeCount":8},[],{"trials":2151,"activeCount":8},[2152],{"nctId":2153,"briefTitle":2154,"status":55,"phases":2155,"start":2156,"enrollment":506,"conditions":2157,"interventions":2158},"NCT00052000","A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer",[39],"2002-11",[20],[2146],{"trials":2160,"activeCount":8},[2161],{"nctId":2162,"briefTitle":2163,"status":55,"phases":2164,"completion":2165,"start":2166,"enrollment":2167,"conditions":2168,"interventions":2169},"NCT00070837","MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer",[39,40],"2004-10","2003-10",46,[34],[2146],{"trials":2171,"activeCount":8},[],{"trials":2173,"activeCount":8},[],{"trials":2175,"activeCount":8},[],{"intervention":521,"totalTrials":1101,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2179,"activeCount":8},[],{"trials":2181,"activeCount":8},[],{"trials":2183,"activeCount":8},[2184,2188],{"nctId":594,"briefTitle":595,"status":55,"phases":2185,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":2186,"interventions":2187},[39,40],[601,14],[603,521,427],{"nctId":511,"briefTitle":512,"status":55,"phases":2189,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":2190,"interventions":2191},[40],[519],[382,521,427],{"trials":2193,"activeCount":8},[],{"trials":2195,"activeCount":8},[],{"trials":2197,"activeCount":8},[],{"intervention":2199,"totalTrials":1101,"cells":2200},"TAK-385",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2216,"PHASE3":2228,"PHASE4":2230,"NA":2232},{"trials":2202,"activeCount":8},[],{"trials":2204,"activeCount":8},[2205],{"nctId":2206,"briefTitle":2207,"status":55,"phases":2208,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":2211,"conditions":2212,"interventions":2214},"NCT02093390","A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects",[39],"2014-04","2014-03",40,[20,2213],"Endometriosis",[2199,1432,2215],"Atorvastatin",{"trials":2217,"activeCount":8},[2218],{"nctId":2219,"briefTitle":2220,"status":55,"phases":2221,"primaryCompletion":2222,"completion":2222,"start":2223,"enrollment":2224,"conditions":2225,"interventions":2226},"NCT02135445","Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer",[40],"2015-12","2014-06",103,[20],[2199,2227],"Degarelix",{"trials":2229,"activeCount":8},[],{"trials":2231,"activeCount":8},[],{"trials":2233,"activeCount":8},[],{"intervention":1446,"totalTrials":1101,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2244,"PHASE3":2250,"PHASE4":2252,"NA":2254},{"trials":2237,"activeCount":8},[],{"trials":2239,"activeCount":8},[2240],{"nctId":1438,"briefTitle":1439,"status":55,"phases":2241,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":484,"conditions":2242,"interventions":2243},[39],[1444],[1446,179],{"trials":2245,"activeCount":8},[2246],{"nctId":1509,"briefTitle":1510,"status":55,"phases":2247,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":2248,"interventions":2249},[40],[1517],[179,1446,177],{"trials":2251,"activeCount":8},[],{"trials":2253,"activeCount":8},[],{"trials":2255,"activeCount":8},[],{"intervention":2257,"totalTrials":1101,"cells":2258},"MLN1202",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2283,"PHASE4":2285,"NA":2287},{"trials":2260,"activeCount":8},[],{"trials":2262,"activeCount":8},[],{"trials":2264,"activeCount":8},[2265,2275],{"nctId":2266,"briefTitle":2267,"status":55,"phases":2268,"primaryCompletion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2274},"NCT00715169","Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease",[40],"2006-04","2005-08",108,[2273],"Atherosclerosis",[2257],{"nctId":2276,"briefTitle":2277,"status":55,"phases":2278,"primaryCompletion":1637,"completion":1616,"start":2279,"enrollment":599,"conditions":2280,"interventions":2282},"NCT01199640","Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis",[40],"2005-05",[2281],"Multiple Sclerosis",[2257],{"trials":2284,"activeCount":8},[],{"trials":2286,"activeCount":8},[],{"trials":2288,"activeCount":8},[],{"intervention":2290,"totalTrials":1101,"cells":2291},"Leuprorelin",{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2293,"activeCount":8},[],{"trials":2295,"activeCount":8},[],{"trials":2297,"activeCount":8},[2298,2309],{"nctId":2299,"briefTitle":2300,"status":55,"phases":2301,"primaryCompletion":2302,"completion":2303,"start":2304,"enrollment":2305,"conditions":2306,"interventions":2307},"NCT02083185","A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer",[40],"2016-01-01","2017-02-23","2014-03-26",136,[20],[2308,2290],"Relugolix",{"nctId":2310,"briefTitle":2311,"status":169,"phases":2312,"primaryCompletion":685,"completion":753,"start":617,"enrollment":195,"conditions":2313,"interventions":2314},"NCT01132404","Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448",[39,40],[20,34],[2290,2315],"TAK-448",{"trials":2317,"activeCount":8},[],{"trials":2319,"activeCount":8},[],{"trials":2321,"activeCount":8},[],{"intervention":2323,"totalTrials":1101,"cells":2324},"TAK-954",{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2338,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2326,"activeCount":8},[],{"trials":2328,"activeCount":8},[2329],{"nctId":2330,"briefTitle":2331,"status":55,"phases":2332,"primaryCompletion":2333,"completion":2333,"start":2334,"enrollment":29,"conditions":2335,"interventions":2336},"NCT03870555","A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants",[39],"2019-05-16","2019-03-08",[23],[2323,2337],"TAK-954 Placebo",{"trials":2339,"activeCount":8},[2340],{"nctId":2341,"briefTitle":2342,"status":169,"phases":2343,"primaryCompletion":2344,"completion":2344,"start":2345,"enrollment":11,"conditions":2346,"interventions":2350},"NCT03477903","TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)",[40],"2018-08-29","2018-08-25",[2347,2348,2349],"Critical Illness","Enteral Nutrition","Enteral Feeding Intolerance",[2323,2351,2352],"Metoclopramide","Normal Saline",{"trials":2354,"activeCount":8},[],{"trials":2356,"activeCount":8},[],{"trials":2358,"activeCount":8},[],{"intervention":2360,"totalTrials":1101,"cells":2361},"VELCADE TM (bortezomib) for Injection, or PS-341",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2374,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[2366],{"nctId":2367,"briefTitle":2368,"status":169,"phases":2369,"start":2104,"enrollment":2167,"conditions":2370,"interventions":2373},"NCT00064636","Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors",[39],[2371,2372],"Advanced Non-Small Cell Lung Cancer","Other Solid Tumors",[2360],{"trials":2375,"activeCount":8},[2376],{"nctId":2377,"briefTitle":2378,"status":55,"phases":2379,"primaryCompletion":2380,"start":2104,"enrollment":2381,"conditions":2382,"interventions":2384},"NCT00051987","Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma",[40],"2004-03",175,[2383],"Colorectal Carcinoma",[2360],{"trials":2386,"activeCount":8},[],{"trials":2388,"activeCount":8},[],{"trials":2390,"activeCount":8},[],{"intervention":2392,"totalTrials":11,"cells":2393},"Orteronel+Prednisone",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2395,"activeCount":8},[],{"trials":2397,"activeCount":8},[],{"trials":2399,"activeCount":8},[2400],{"nctId":2401,"briefTitle":2402,"status":55,"phases":2403,"primaryCompletion":2404,"completion":2404,"start":683,"enrollment":599,"conditions":2405,"interventions":2406},"NCT01549951","Study to Investigate the Effects of Orteronel on the QT\u002FQTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer",[40],"2015-01",[20],[2392],{"trials":2408,"activeCount":8},[],{"trials":2410,"activeCount":8},[],{"trials":2412,"activeCount":8},[],{"intervention":2414,"totalTrials":11,"cells":2415},"pegylated liposomal doxorubicin",{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2417,"activeCount":8},[],{"trials":2419,"activeCount":8},[],{"trials":2421,"activeCount":8},[2422],{"nctId":2423,"briefTitle":2424,"status":431,"phases":2425,"primaryCompletion":901,"start":2426,"enrollment":2427,"conditions":2428,"interventions":2429},"NCT00610792","Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens",[40],"2006-07",91,[197],[2430,2414],"bortezomib",{"trials":2432,"activeCount":8},[],{"trials":2434,"activeCount":8},[],{"trials":2436,"activeCount":8},[],{"intervention":603,"totalTrials":11,"cells":2438},{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2443,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2440,"activeCount":8},[],{"trials":2442,"activeCount":8},[],{"trials":2444,"activeCount":8},[2445],{"nctId":594,"briefTitle":595,"status":55,"phases":2446,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":2447,"interventions":2448},[39,40],[601,14],[603,521,427],{"trials":2450,"activeCount":8},[],{"trials":2452,"activeCount":8},[],{"trials":2454,"activeCount":8},[],{"intervention":2227,"totalTrials":11,"cells":2456},{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2461,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2458,"activeCount":8},[],{"trials":2460,"activeCount":8},[],{"trials":2462,"activeCount":8},[2463],{"nctId":2219,"briefTitle":2220,"status":55,"phases":2464,"primaryCompletion":2222,"completion":2222,"start":2223,"enrollment":2224,"conditions":2465,"interventions":2466},[40],[20],[2199,2227],{"trials":2468,"activeCount":8},[],{"trials":2470,"activeCount":8},[],{"trials":2472,"activeCount":8},[],{"intervention":2474,"totalTrials":11,"cells":2475},"MLN8237",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2477,"activeCount":8},[],{"trials":2479,"activeCount":8},[],{"trials":2481,"activeCount":8},[2482],{"nctId":2483,"briefTitle":2484,"status":55,"phases":2485,"primaryCompletion":1672,"completion":2209,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2493},"NCT01045421","Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies",[39,40],"2010-02",273,[2489,1618,198,2490,2491,2492],"Advanced Nonhematological Malignancies","Metastatic Breast Cancer","Head and Neck Squamous Cell Carcinoma","Gastroesophageal Adenocarcinoma",[2474],{"trials":2495,"activeCount":8},[],{"trials":2497,"activeCount":8},[],{"trials":2499,"activeCount":8},[],{"intervention":1876,"totalTrials":11,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2503,"activeCount":8},[],{"trials":2505,"activeCount":8},[],{"trials":2507,"activeCount":8},[2508],{"nctId":1868,"briefTitle":1869,"status":55,"phases":2509,"primaryCompletion":1871,"completion":1871,"start":1872,"enrollment":1429,"conditions":2510,"interventions":2511},[40],[1874],[1851,1876,1877],{"trials":2513,"activeCount":8},[],{"trials":2515,"activeCount":8},[],{"trials":2517,"activeCount":8},[],{"intervention":1877,"totalTrials":11,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2521,"activeCount":8},[],{"trials":2523,"activeCount":8},[],{"trials":2525,"activeCount":8},[2526],{"nctId":1868,"briefTitle":1869,"status":55,"phases":2527,"primaryCompletion":1871,"completion":1871,"start":1872,"enrollment":1429,"conditions":2528,"interventions":2529},[40],[1874],[1851,1876,1877],{"trials":2531,"activeCount":8},[],{"trials":2533,"activeCount":8},[],{"trials":2535,"activeCount":8},[],{"intervention":905,"totalTrials":11,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2539,"activeCount":8},[],{"trials":2541,"activeCount":8},[],{"trials":2543,"activeCount":8},[2544],{"nctId":897,"briefTitle":898,"status":169,"phases":2545,"primaryCompletion":685,"completion":900,"start":901,"enrollment":902,"conditions":2546,"interventions":2547},[40],[508],[905,813,622],{"trials":2549,"activeCount":8},[],{"trials":2551,"activeCount":8},[],{"trials":2553,"activeCount":8},[],{"intervention":2555,"totalTrials":11,"cells":2556},"VELCADE™",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2558,"activeCount":8},[],{"trials":2560,"activeCount":8},[],{"trials":2562,"activeCount":8},[2563],{"nctId":2564,"briefTitle":2565,"status":55,"phases":2566,"primaryCompletion":2567,"start":2104,"enrollment":2568,"conditions":2569,"interventions":2570},"NCT00051974","Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer",[40],"2004-09",155,[1618],[2555],{"trials":2572,"activeCount":8},[],{"trials":2574,"activeCount":8},[],{"trials":2576,"activeCount":8},[],{"intervention":1620,"totalTrials":11,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2580,"activeCount":8},[],{"trials":2582,"activeCount":8},[],{"trials":2584,"activeCount":8},[2585],{"nctId":1613,"briefTitle":1614,"status":55,"phases":2586,"primaryCompletion":1616,"conditions":2587,"interventions":2588},[40],[1618],[622,1620],{"trials":2590,"activeCount":8},[],{"trials":2592,"activeCount":8},[],{"trials":2594,"activeCount":8},[],{"intervention":2596,"totalTrials":11,"cells":2597},"bortezomib, dexamethasone, and thalidomide",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2599,"activeCount":8},[],{"trials":2601,"activeCount":8},[],{"trials":2603,"activeCount":8},[2604],{"nctId":2605,"briefTitle":2606,"status":55,"phases":2607,"primaryCompletion":2608,"completion":2609,"start":1616,"enrollment":2610,"conditions":2611,"interventions":2612},"NCT00531453","A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma",[40],"2009-04","2009-05",98,[14],[2596,2613],"bortezomib, dexamethasone, thalidomide, and cyclophosphamide",{"trials":2615,"activeCount":8},[],{"trials":2617,"activeCount":8},[],{"trials":2619,"activeCount":8},[],{"intervention":2613,"totalTrials":11,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2623,"activeCount":8},[],{"trials":2625,"activeCount":8},[],{"trials":2627,"activeCount":8},[2628],{"nctId":2605,"briefTitle":2606,"status":55,"phases":2629,"primaryCompletion":2608,"completion":2609,"start":1616,"enrollment":2610,"conditions":2630,"interventions":2631},[40],[14],[2596,2613],{"trials":2633,"activeCount":8},[],{"trials":2635,"activeCount":8},[],{"trials":2637,"activeCount":8},[],{"intervention":1697,"totalTrials":11,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2641,"activeCount":8},[],{"trials":2643,"activeCount":8},[],{"trials":2645,"activeCount":8},[2646],{"nctId":1687,"briefTitle":1688,"status":55,"phases":2647,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":1693,"conditions":2648,"interventions":2649},[40],[1695],[1697,285,177],{"trials":2651,"activeCount":8},[],{"trials":2653,"activeCount":8},[],{"trials":2655,"activeCount":8},[],{"intervention":2657,"totalTrials":11,"cells":2658},"LDP-02",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2660,"activeCount":8},[],{"trials":2662,"activeCount":8},[],{"trials":2664,"activeCount":8},[2665],{"nctId":2666,"briefTitle":2667,"status":55,"phases":2668,"primaryCompletion":2669,"start":2670,"enrollment":2671,"conditions":2672,"interventions":2673},"NCT00655135","Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients",[40],"2002-06","2000-02",185,[724],[2657],{"trials":2675,"activeCount":8},[],{"trials":2677,"activeCount":8},[],{"trials":2679,"activeCount":8},[],{"intervention":2681,"totalTrials":11,"cells":2682},"TAK-653",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2684,"activeCount":8},[],{"trials":2686,"activeCount":8},[],{"trials":2688,"activeCount":8},[2689],{"nctId":2690,"briefTitle":2691,"status":431,"phases":2692,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":8,"conditions":2696,"interventions":2698},"NCT03312894","Efficacy and Safety of TAK-653 in Treatment-Resistant Depression",[40],"2019-02-28","2019-09-30","2018-02-15",[2697],"Treatment-Resistant Depression",[2681],{"trials":2700,"activeCount":8},[],{"trials":2702,"activeCount":8},[],{"trials":2704,"activeCount":8},[],{"intervention":2706,"totalTrials":11,"cells":2707},"Soticlestat",{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2709,"activeCount":8},[],{"trials":2711,"activeCount":8},[],{"trials":2713,"activeCount":8},[2714],{"nctId":2715,"briefTitle":2716,"status":55,"phases":2717,"primaryCompletion":2718,"completion":2719,"start":2720,"enrollment":15,"conditions":2721,"interventions":2723},"NCT03990649","Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)",[40],"2020-06-29","2020-10-28","2019-07-23",[2722],"Complex Regional Pain Syndrome",[2706],{"trials":2725,"activeCount":8},[],{"trials":2727,"activeCount":8},[],{"trials":2729,"activeCount":8},[],{"intervention":2731,"totalTrials":11,"cells":2732},"VELCADE and rituximab",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2734,"activeCount":8},[],{"trials":2736,"activeCount":8},[],{"trials":2738,"activeCount":8},[2739],{"nctId":2740,"briefTitle":2741,"status":55,"phases":2742,"primaryCompletion":2269,"start":2743,"enrollment":2744,"conditions":2745,"interventions":2748},"NCT00085696","VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma",[40],"2004-05",66,[2746,508,2747],"B-Cell Lymphoma","Marginal Lymphoma",[2731],{"trials":2750,"activeCount":8},[],{"trials":2752,"activeCount":8},[],{"trials":2754,"activeCount":8},[],{"intervention":2308,"totalTrials":11,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":8},[],{"trials":2760,"activeCount":8},[],{"trials":2762,"activeCount":8},[2763],{"nctId":2299,"briefTitle":2300,"status":55,"phases":2764,"primaryCompletion":2302,"completion":2303,"start":2304,"enrollment":2305,"conditions":2765,"interventions":2766},[40],[20],[2308,2290],{"trials":2768,"activeCount":8},[],{"trials":2770,"activeCount":8},[],{"trials":2772,"activeCount":8},[],{"intervention":2315,"totalTrials":11,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2785,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":8},[],{"trials":2778,"activeCount":8},[],{"trials":2780,"activeCount":8},[2781],{"nctId":2310,"briefTitle":2311,"status":169,"phases":2782,"primaryCompletion":685,"completion":753,"start":617,"enrollment":195,"conditions":2783,"interventions":2784},[39,40],[20,34],[2290,2315],{"trials":2786,"activeCount":8},[],{"trials":2788,"activeCount":8},[],{"trials":2790,"activeCount":8},[],{"intervention":625,"totalTrials":11,"cells":2792},{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2794,"activeCount":8},[],{"trials":2796,"activeCount":8},[],{"trials":2798,"activeCount":8},[2799],{"nctId":613,"briefTitle":614,"status":55,"phases":2800,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":2801,"interventions":2802},[39,40],[14],[622,623,624,625],{"trials":2804,"activeCount":8},[],{"trials":2806,"activeCount":8},[],{"trials":2808,"activeCount":8},[],{"intervention":2810,"totalTrials":11,"cells":2811},"tandutinib",{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2824,"PHASE4":2826,"NA":2828},{"trials":2813,"activeCount":8},[],{"trials":2815,"activeCount":8},[],{"trials":2817,"activeCount":8},[2818],{"nctId":2819,"briefTitle":2820,"status":431,"phases":2821,"enrollment":8,"conditions":2822,"interventions":2823},"NCT00297921","A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy",[39,40],[28],[2810],{"trials":2825,"activeCount":8},[],{"trials":2827,"activeCount":8},[],{"trials":2829,"activeCount":8},[],{"intervention":2831,"totalTrials":11,"cells":2832},"erlotinib and bortezomib",{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2846,"PHASE4":2848,"NA":2850},{"trials":2834,"activeCount":8},[],{"trials":2836,"activeCount":8},[],{"trials":2838,"activeCount":8},[2839],{"nctId":2840,"briefTitle":2841,"status":169,"phases":2842,"primaryCompletion":1637,"completion":618,"start":2270,"conditions":2843,"interventions":2845},"NCT00283634","A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer",[40],[2844],"NSCLC",[2831],{"trials":2847,"activeCount":8},[],{"trials":2849,"activeCount":8},[],{"trials":2851,"activeCount":8},[],{"intervention":2351,"totalTrials":11,"cells":2853},{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2864,"PHASE4":2866,"NA":2868},{"trials":2855,"activeCount":8},[],{"trials":2857,"activeCount":8},[],{"trials":2859,"activeCount":8},[2860],{"nctId":2341,"briefTitle":2342,"status":169,"phases":2861,"primaryCompletion":2344,"completion":2344,"start":2345,"enrollment":11,"conditions":2862,"interventions":2863},[40],[2347,2348,2349],[2323,2351,2352],{"trials":2865,"activeCount":8},[],{"trials":2867,"activeCount":8},[],{"trials":2869,"activeCount":8},[],{"intervention":2352,"totalTrials":11,"cells":2871},{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2873,"activeCount":8},[],{"trials":2875,"activeCount":8},[],{"trials":2877,"activeCount":8},[2878],{"nctId":2341,"briefTitle":2342,"status":169,"phases":2879,"primaryCompletion":2344,"completion":2344,"start":2345,"enrollment":11,"conditions":2880,"interventions":2881},[40],[2347,2348,2349],[2323,2351,2352],{"trials":2883,"activeCount":8},[],{"trials":2885,"activeCount":8},[],{"trials":2887,"activeCount":8},[],{"intervention":1060,"totalTrials":454,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2934,"PHASE3":2936,"PHASE4":2938,"NA":2940},{"trials":2891,"activeCount":8},[],{"trials":2893,"activeCount":8},[2894,2898,2902,2906,2914,2922,2926],{"nctId":1424,"briefTitle":1425,"status":55,"phases":2895,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":2896,"interventions":2897},[39],[17],[1060,1432,222,165,1061,179],{"nctId":1053,"briefTitle":1054,"status":55,"phases":2899,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":496,"conditions":2900,"interventions":2901},[39],[130],[1060,179,375,165,1061],{"nctId":1988,"briefTitle":1989,"status":55,"phases":2903,"primaryCompletion":394,"completion":1991,"start":1992,"enrollment":722,"conditions":2904,"interventions":2905},[39],[28,1994,1995],[1060,1843],{"nctId":2907,"briefTitle":2908,"status":55,"phases":2909,"primaryCompletion":1673,"completion":2910,"start":699,"enrollment":2911,"conditions":2912,"interventions":2913},"NCT00722488","Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma",[39],"2013-09",56,[396,14,25,62],[1060],{"nctId":2915,"briefTitle":2916,"status":55,"phases":2917,"primaryCompletion":732,"completion":2918,"start":1961,"enrollment":2919,"conditions":2920,"interventions":2921},"NCT00677170","Study of MLN4924 in Adult Patients With Nonhematologic Malignancies",[39],"2012-12",62,[31],[1060],{"nctId":1998,"briefTitle":1999,"status":55,"phases":2923,"primaryCompletion":2001,"completion":2002,"start":2003,"enrollment":496,"conditions":2924,"interventions":2925},[39],[28],[1060,1843],{"nctId":2927,"briefTitle":2928,"status":55,"phases":2929,"primaryCompletion":683,"completion":820,"start":2930,"enrollment":560,"conditions":2931,"interventions":2933},"NCT01011530","Dose Escalation Study of MLN4924 in Adults With Melanoma",[39],"2009-12",[2932],"Metastatic Melanoma",[1060],{"trials":2935,"activeCount":8},[],{"trials":2937,"activeCount":8},[],{"trials":2939,"activeCount":8},[],{"trials":2941,"activeCount":8},[],{"intervention":1061,"totalTrials":32,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2968,"PHASE3":2970,"PHASE4":2972,"NA":2974},{"trials":2945,"activeCount":8},[],{"trials":2947,"activeCount":8},[2948,2952,2956,2960,2964],{"nctId":1424,"briefTitle":1425,"status":55,"phases":2949,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":2950,"interventions":2951},[39],[17],[1060,1432,222,165,1061,179],{"nctId":1053,"briefTitle":1054,"status":55,"phases":2953,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":496,"conditions":2954,"interventions":2955},[39],[130],[1060,179,375,165,1061],{"nctId":1468,"briefTitle":1469,"status":55,"phases":2957,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":26,"conditions":2958,"interventions":2959},[39],[1475],[1477,1478,165,1061,179],{"nctId":1480,"briefTitle":1481,"status":55,"phases":2961,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":60,"conditions":2962,"interventions":2963},[39],[1487],[1477,133,165,1061,179],{"nctId":1490,"briefTitle":1491,"status":55,"phases":2965,"primaryCompletion":1493,"completion":1494,"start":1495,"enrollment":1453,"conditions":2966,"interventions":2967},[39],[1487],[1477,165,1061,179],{"trials":2969,"activeCount":8},[],{"trials":2971,"activeCount":8},[],{"trials":2973,"activeCount":8},[],{"trials":2975,"activeCount":8},[],{"intervention":133,"totalTrials":32,"cells":2977},{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":3025,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":2979,"activeCount":8},[],{"trials":2981,"activeCount":8},[2982,2986,3002,3012,3021],{"nctId":122,"briefTitle":123,"status":55,"phases":2983,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":2984,"interventions":2985},[39],[130,25],[114,132,133],{"nctId":2987,"briefTitle":2988,"status":55,"phases":2989,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":2993,"conditions":2994,"interventions":2996},"NCT01454076","Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma",[39],"2015-04-01","2016-06-16","2011-11-10",112,[2995,25],"Nonhematologic Malignancies",[2997,2998,2999,3000,133,3001,2999],"Ixazomib 2.5 mg","Ixazomib 4 mg Capsule A","Ixazomib 4 mg Capsule B","Ketoconazole","Clarithromycin",{"nctId":3003,"briefTitle":3004,"status":55,"phases":3005,"primaryCompletion":3006,"completion":3007,"start":3008,"enrollment":902,"conditions":3009,"interventions":3010},"NCT04121078","A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants",[39],"2019-11-04","2019-11-16","2019-10-15",[23],[3011,133],"TAK-906",{"nctId":3013,"briefTitle":3014,"status":55,"phases":3015,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":15,"conditions":3018,"interventions":3019},"NCT03928327","A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants",[39],"2019-08-16","2019-05-02",[23],[3020,222,133],"TAK-788",{"nctId":1480,"briefTitle":1481,"status":55,"phases":3022,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":60,"conditions":3023,"interventions":3024},[39],[1487],[1477,133,165,1061,179],{"trials":3026,"activeCount":8},[],{"trials":3028,"activeCount":8},[],{"trials":3030,"activeCount":8},[],{"trials":3032,"activeCount":8},[],{"intervention":222,"totalTrials":35,"cells":3034},{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3036,"activeCount":8},[],{"trials":3038,"activeCount":8},[3039,3043,3047,3051],{"nctId":1424,"briefTitle":1425,"status":55,"phases":3040,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":3041,"interventions":3042},[39],[17],[1060,1432,222,165,1061,179],{"nctId":1858,"briefTitle":1859,"status":55,"phases":3044,"primaryCompletion":1861,"completion":295,"start":1427,"enrollment":902,"conditions":3045,"interventions":3046},[39],[1863],[1851,222],{"nctId":3013,"briefTitle":3014,"status":55,"phases":3048,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":15,"conditions":3049,"interventions":3050},[39],[23],[3020,222,133],{"nctId":213,"briefTitle":214,"status":55,"phases":3052,"primaryCompletion":216,"completion":217,"start":218,"enrollment":15,"conditions":3053,"interventions":3054},[39],[17,220],[114,222],{"trials":3056,"activeCount":8},[],{"trials":3058,"activeCount":8},[],{"trials":3060,"activeCount":8},[],{"trials":3062,"activeCount":8},[],{"intervention":132,"totalTrials":239,"cells":3064},{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3085,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3066,"activeCount":8},[],{"trials":3068,"activeCount":8},[3069,3073,3081],{"nctId":122,"briefTitle":123,"status":55,"phases":3070,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":3071,"interventions":3072},[39],[130,25],[114,132,133],{"nctId":3074,"briefTitle":3075,"status":55,"phases":3076,"primaryCompletion":3077,"completion":3077,"start":3078,"enrollment":902,"conditions":3079,"interventions":3080},"NCT03849690","A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants",[39],"2019-04-15","2019-02-27",[23],[3011,132],{"nctId":2061,"briefTitle":2062,"status":55,"phases":3082,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":60,"conditions":3083,"interventions":3084},[39],[2067],[2069,2045,132],{"trials":3086,"activeCount":8},[],{"trials":3088,"activeCount":8},[],{"trials":3090,"activeCount":8},[],{"trials":3092,"activeCount":8},[],{"intervention":3094,"totalTrials":239,"cells":3095},"Mobocertinib",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3127,"PHASE3":3129,"PHASE4":3131,"NA":3133},{"trials":3097,"activeCount":8},[],{"trials":3099,"activeCount":8},[3100,3110,3119],{"nctId":3101,"briefTitle":3102,"status":55,"phases":3103,"primaryCompletion":3104,"completion":3105,"start":3106,"enrollment":15,"conditions":3107,"interventions":3109},"NCT04056468","A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function",[39],"2022-02-05","2022-02-26","2020-10-09",[3108,23],"Hepatic Impairment",[3094],{"nctId":3111,"briefTitle":3112,"status":55,"phases":3113,"primaryCompletion":3114,"completion":3114,"start":3115,"enrollment":141,"conditions":3116,"interventions":3118},"NCT04056455","A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys",[39],"2022-04-20","2020-03-04",[3117,23],"Renal Impairment",[3094],{"nctId":3120,"briefTitle":3121,"status":55,"phases":3122,"primaryCompletion":3123,"completion":3123,"start":3124,"enrollment":454,"conditions":3125,"interventions":3126},"NCT03811834","A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants",[39],"2019-03-11","2019-01-22",[23],[3094],{"trials":3128,"activeCount":8},[],{"trials":3130,"activeCount":8},[],{"trials":3132,"activeCount":8},[],{"trials":3134,"activeCount":8},[],{"intervention":3011,"totalTrials":239,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3160,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3138,"activeCount":8},[],{"trials":3140,"activeCount":8},[3141,3145,3156],{"nctId":3074,"briefTitle":3075,"status":55,"phases":3142,"primaryCompletion":3077,"completion":3077,"start":3078,"enrollment":902,"conditions":3143,"interventions":3144},[39],[23],[3011,132],{"nctId":3146,"briefTitle":3147,"status":55,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":29,"conditions":3151,"interventions":3152},"NCT04454918","Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants",[39],"2020-09-30","2020-07-30",[23],[3153,3154,3155],"TAK-906 Oral","[14C]-TAK-906 Intravenous","[14C]-TAK-906 Oral Solution",{"nctId":3003,"briefTitle":3004,"status":55,"phases":3157,"primaryCompletion":3006,"completion":3007,"start":3008,"enrollment":902,"conditions":3158,"interventions":3159},[39],[23],[3011,133],{"trials":3161,"activeCount":8},[],{"trials":3163,"activeCount":8},[],{"trials":3165,"activeCount":8},[],{"trials":3167,"activeCount":8},[],{"intervention":3020,"totalTrials":239,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3199,"PHASE3":3201,"PHASE4":3203,"NA":3205},{"trials":3171,"activeCount":8},[],{"trials":3173,"activeCount":8},[3174,3178,3189],{"nctId":3013,"briefTitle":3014,"status":55,"phases":3175,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":15,"conditions":3176,"interventions":3177},[39],[23],[3020,222,133],{"nctId":3179,"briefTitle":3180,"status":55,"phases":3181,"primaryCompletion":3182,"completion":3183,"start":3184,"enrollment":141,"conditions":3185,"interventions":3187},"NCT04051827","Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)",[39],"2020-12-17","2021-12-07","2019-12-23",[1640,3186],"Lung Neoplasms",[3188,3020],"Midazolam",{"nctId":3190,"briefTitle":3191,"status":55,"phases":3192,"primaryCompletion":3193,"completion":3194,"start":3195,"enrollment":3196,"conditions":3197,"interventions":3198},"NCT03482453","A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants",[39],"2018-12-22","2019-01-18","2018-03-28",69,[23],[3020,3020],{"trials":3200,"activeCount":8},[],{"trials":3202,"activeCount":8},[],{"trials":3204,"activeCount":8},[],{"trials":3206,"activeCount":8},[],{"intervention":178,"totalTrials":1101,"cells":3208},{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3221,"PHASE3":3223,"PHASE4":3225,"NA":3227},{"trials":3210,"activeCount":8},[],{"trials":3212,"activeCount":8},[3213,3217],{"nctId":876,"briefTitle":877,"status":169,"phases":3214,"primaryCompletion":879,"completion":879,"start":880,"enrollment":423,"conditions":3215,"interventions":3216},[39],[882],[178,884,335,375,426,885],{"nctId":167,"briefTitle":168,"status":169,"phases":3218,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":3219,"interventions":3220},[39],[175],[177,178,114,179,165],{"trials":3222,"activeCount":8},[],{"trials":3224,"activeCount":8},[],{"trials":3226,"activeCount":8},[],{"trials":3228,"activeCount":8},[],{"intervention":1432,"totalTrials":1101,"cells":3230},{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3243,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3232,"activeCount":8},[],{"trials":3234,"activeCount":8},[3235,3239],{"nctId":1424,"briefTitle":1425,"status":55,"phases":3236,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":3237,"interventions":3238},[39],[17],[1060,1432,222,165,1061,179],{"nctId":2206,"briefTitle":2207,"status":55,"phases":3240,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":2211,"conditions":3241,"interventions":3242},[39],[20,2213],[2199,1432,2215],{"trials":3244,"activeCount":8},[],{"trials":3246,"activeCount":8},[],{"trials":3248,"activeCount":8},[],{"trials":3250,"activeCount":8},[],{"intervention":3252,"totalTrials":1101,"cells":3253},"MLN8054",{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3279,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3255,"activeCount":8},[],{"trials":3257,"activeCount":8},[3258,3271],{"nctId":3259,"briefTitle":3260,"status":169,"phases":3261,"primaryCompletion":3262,"start":3263,"enrollment":3264,"conditions":3265,"interventions":3270},"NCT00249301","A Study of MLN8054 in Patients With Advanced Solid Tumors",[39],"2008-01","2005-10",63,[3266,3267,3268,3269],"Breast Neoplasm","Colon Neoplasm","Pancreatic Neoplasm","Bladder Neoplasm",[3252],{"nctId":3272,"briefTitle":3273,"status":169,"phases":3274,"primaryCompletion":3275,"completion":1961,"start":2269,"enrollment":3276,"conditions":3277,"interventions":3278},"NCT00652158","A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies",[39],"2008-03",44,[209],[3252],{"trials":3280,"activeCount":8},[],{"trials":3282,"activeCount":8},[],{"trials":3284,"activeCount":8},[],{"trials":3286,"activeCount":8},[],{"intervention":3288,"totalTrials":1101,"cells":3289},"TAK-901",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3318,"PHASE3":3320,"PHASE4":3322,"NA":3324},{"trials":3291,"activeCount":8},[],{"trials":3293,"activeCount":8},[3294,3302],{"nctId":3295,"briefTitle":3296,"status":55,"phases":3297,"primaryCompletion":3298,"completion":3299,"start":795,"enrollment":60,"conditions":3300,"interventions":3301},"NCT00935844","Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma",[39],"2011-08","2011-11",[17,25],[3288],{"nctId":3303,"briefTitle":3304,"status":55,"phases":3305,"primaryCompletion":3306,"completion":644,"start":3307,"enrollment":344,"conditions":3308,"interventions":3317},"NCT00807677","A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies",[39],"2012-09","2009-03",[3309,1994,3310,3311,14,258,1995,3312,3313,3314,3315,3316],"Acute Myeloid Leukemia","Chronic Myelogenous Leukemia","Chronic Lymphocytic Leukemia","Philadelphia Chromosome-negative CML","Myeloid Metaplasia","Myelofibrosis","Advanced Polycythemia","Non-Hodgkins Lymphoma",[3288],{"trials":3319,"activeCount":8},[],{"trials":3321,"activeCount":8},[],{"trials":3323,"activeCount":8},[],{"trials":3325,"activeCount":8},[],{"intervention":284,"totalTrials":1101,"cells":3327},{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3347,"PHASE3":3349,"PHASE4":3351,"NA":3353},{"trials":3329,"activeCount":8},[],{"trials":3331,"activeCount":8},[3332,3343],{"nctId":3333,"briefTitle":3334,"status":55,"phases":3335,"primaryCompletion":421,"completion":3336,"start":3337,"enrollment":3338,"conditions":3339,"interventions":3342},"NCT01425008","Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma",[39],"2018-10-16","2011-09-15",149,[673,2932,3340,3341],"Solid Tumor","Neoplasm",[284],{"nctId":276,"briefTitle":277,"status":55,"phases":3344,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":3345,"interventions":3346},[39],[31],[284,285,114,179,286,287],{"trials":3348,"activeCount":8},[],{"trials":3350,"activeCount":8},[],{"trials":3352,"activeCount":8},[],{"trials":3354,"activeCount":8},[],{"intervention":3356,"totalTrials":1101,"cells":3357},"TAK-925",{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3384,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3359,"activeCount":8},[],{"trials":3361,"activeCount":8},[3362,3372],{"nctId":3363,"briefTitle":3364,"status":55,"phases":3365,"primaryCompletion":3366,"completion":3366,"start":3367,"enrollment":3368,"conditions":3369,"interventions":3371},"NCT04091425","Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)",[39],"2020-04-02","2019-11-21",25,[3370],"Obstructive Sleep Apnea",[3356],{"nctId":3373,"briefTitle":3374,"status":55,"phases":3375,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":3379,"conditions":3380,"interventions":3382},"NCT04091438","A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia",[39],"2020-11-19","2020-11-23","2020-01-26",28,[3381],"Idiopathic Hypersomnia",[3356,3383],"TAK-925 Placebo",{"trials":3385,"activeCount":8},[],{"trials":3387,"activeCount":8},[],{"trials":3389,"activeCount":8},[],{"trials":3391,"activeCount":8},[],{"intervention":885,"totalTrials":11,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3402,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3395,"activeCount":8},[],{"trials":3397,"activeCount":8},[3398],{"nctId":876,"briefTitle":877,"status":169,"phases":3399,"primaryCompletion":879,"completion":879,"start":880,"enrollment":423,"conditions":3400,"interventions":3401},[39],[882],[178,884,335,375,426,885],{"trials":3403,"activeCount":8},[],{"trials":3405,"activeCount":8},[],{"trials":3407,"activeCount":8},[],{"trials":3409,"activeCount":8},[],{"intervention":3411,"totalTrials":11,"cells":3412},"omeprazole and bortezomib",{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3425,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3414,"activeCount":8},[],{"trials":3416,"activeCount":8},[3417],{"nctId":3418,"briefTitle":3419,"status":55,"phases":3420,"enrollment":60,"conditions":3421,"interventions":3424},"NCT00298779","Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.",[39],[3422,3423],"Tumors","Non-Hodgkins's Lymphoma",[3411],{"trials":3426,"activeCount":8},[],{"trials":3428,"activeCount":8},[],{"trials":3430,"activeCount":8},[],{"trials":3432,"activeCount":8},[],{"intervention":675,"totalTrials":11,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3443,"PHASE3":3445,"PHASE4":3447,"NA":3449},{"trials":3436,"activeCount":8},[],{"trials":3438,"activeCount":8},[3439],{"nctId":666,"briefTitle":667,"status":169,"phases":3440,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":3441,"interventions":3442},[39],[673],[675,676,659,677,678],{"trials":3444,"activeCount":8},[],{"trials":3446,"activeCount":8},[],{"trials":3448,"activeCount":8},[],{"trials":3450,"activeCount":8},[],{"intervention":676,"totalTrials":11,"cells":3452},{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3461,"PHASE3":3463,"PHASE4":3465,"NA":3467},{"trials":3454,"activeCount":8},[],{"trials":3456,"activeCount":8},[3457],{"nctId":666,"briefTitle":667,"status":169,"phases":3458,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":3459,"interventions":3460},[39],[673],[675,676,659,677,678],{"trials":3462,"activeCount":8},[],{"trials":3464,"activeCount":8},[],{"trials":3466,"activeCount":8},[],{"trials":3468,"activeCount":8},[],{"intervention":677,"totalTrials":11,"cells":3470},{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3479,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3472,"activeCount":8},[],{"trials":3474,"activeCount":8},[3475],{"nctId":666,"briefTitle":667,"status":169,"phases":3476,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":3477,"interventions":3478},[39],[673],[675,676,659,677,678],{"trials":3480,"activeCount":8},[],{"trials":3482,"activeCount":8},[],{"trials":3484,"activeCount":8},[],{"trials":3486,"activeCount":8},[],{"intervention":678,"totalTrials":11,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3490,"activeCount":8},[],{"trials":3492,"activeCount":8},[3493],{"nctId":666,"briefTitle":667,"status":169,"phases":3494,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":3495,"interventions":3496},[39],[673],[675,676,659,677,678],{"trials":3498,"activeCount":8},[],{"trials":3500,"activeCount":8},[],{"trials":3502,"activeCount":8},[],{"trials":3504,"activeCount":8},[],{"intervention":3506,"totalTrials":11,"cells":3507},"TAK-441",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3520,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3509,"activeCount":8},[],{"trials":3511,"activeCount":8},[3512],{"nctId":3513,"briefTitle":3514,"status":55,"phases":3515,"primaryCompletion":2918,"completion":820,"start":616,"enrollment":3516,"conditions":3517,"interventions":3519},"NCT01204073","A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies",[39],34,[31,3518],"Carcinoma, Basal Cell",[3506],{"trials":3521,"activeCount":8},[],{"trials":3523,"activeCount":8},[],{"trials":3525,"activeCount":8},[],{"trials":3527,"activeCount":8},[],{"intervention":3529,"totalTrials":11,"cells":3530},"TAK-285 Dose Escalation Cohorts",{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3544,"PHASE3":3546,"PHASE4":3548,"NA":3550},{"trials":3532,"activeCount":8},[],{"trials":3534,"activeCount":8},[3535],{"nctId":3536,"briefTitle":3537,"status":55,"phases":3538,"primaryCompletion":3539,"completion":3539,"start":618,"enrollment":2911,"conditions":3540,"interventions":3542},"NCT00535522","A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer",[39],"2011-06",[3541],"Cancer",[3529,3543],"TAK-285 Recommended Phase 2 Dosing Cohort",{"trials":3545,"activeCount":8},[],{"trials":3547,"activeCount":8},[],{"trials":3549,"activeCount":8},[],{"trials":3551,"activeCount":8},[],{"intervention":3543,"totalTrials":11,"cells":3553},{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3568},{"trials":3555,"activeCount":8},[],{"trials":3557,"activeCount":8},[3558],{"nctId":3536,"briefTitle":3537,"status":55,"phases":3559,"primaryCompletion":3539,"completion":3539,"start":618,"enrollment":2911,"conditions":3560,"interventions":3561},[39],[3541],[3529,3543],{"trials":3563,"activeCount":8},[],{"trials":3565,"activeCount":8},[],{"trials":3567,"activeCount":8},[],{"trials":3569,"activeCount":8},[],{"intervention":3571,"totalTrials":11,"cells":3572},"Ixazomib citrate",{"EARLY_PHASE1":3573,"PHASE1":3575,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3574,"activeCount":8},[],{"trials":3576,"activeCount":8},[3577],{"nctId":3578,"briefTitle":3579,"status":55,"phases":3580,"primaryCompletion":3306,"completion":3581,"start":795,"enrollment":108,"conditions":3582,"interventions":3583},"NCT00963820","Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma",[39],"2014-01",[14],[3571],{"trials":3585,"activeCount":8},[],{"trials":3587,"activeCount":8},[],{"trials":3589,"activeCount":8},[],{"trials":3591,"activeCount":8},[],{"intervention":3593,"totalTrials":11,"cells":3594},"MLN7243",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3608,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3596,"activeCount":8},[],{"trials":3598,"activeCount":8},[3599],{"nctId":3600,"briefTitle":3601,"status":169,"phases":3602,"primaryCompletion":3603,"completion":3603,"start":3604,"enrollment":506,"conditions":3605,"interventions":3607},"NCT02045095","A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors",[39],"2016-11-09","2014-01-31",[3606],"Advanced Malignant Solid Tumors",[3593],{"trials":3609,"activeCount":8},[],{"trials":3611,"activeCount":8},[],{"trials":3613,"activeCount":8},[],{"trials":3615,"activeCount":8},[],{"intervention":1720,"totalTrials":11,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3626,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3619,"activeCount":8},[],{"trials":3621,"activeCount":8},[3622],{"nctId":1711,"briefTitle":1712,"status":55,"phases":3623,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":1717,"conditions":3624,"interventions":3625},[39],[31],[1720,1575],{"trials":3627,"activeCount":8},[],{"trials":3629,"activeCount":8},[],{"trials":3631,"activeCount":8},[],{"trials":3633,"activeCount":8},[],{"intervention":3635,"totalTrials":11,"cells":3636},"TAK-164",{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3638,"activeCount":8},[],{"trials":3640,"activeCount":8},[3641],{"nctId":3642,"briefTitle":3643,"status":169,"phases":3644,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":344,"conditions":3647,"interventions":3649},"NCT03449030","A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)",[39],"2020-02-27","2018-04-23",[3648],"Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies",[3635,3650],"89Zr-TAK-164",{"trials":3652,"activeCount":8},[],{"trials":3654,"activeCount":8},[],{"trials":3656,"activeCount":8},[],{"trials":3658,"activeCount":8},[],{"intervention":3650,"totalTrials":11,"cells":3660},{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3675},{"trials":3662,"activeCount":8},[],{"trials":3664,"activeCount":8},[3665],{"nctId":3642,"briefTitle":3643,"status":169,"phases":3666,"primaryCompletion":3645,"completion":3645,"start":3646,"enrollment":344,"conditions":3667,"interventions":3668},[39],[3648],[3635,3650],{"trials":3670,"activeCount":8},[],{"trials":3672,"activeCount":8},[],{"trials":3674,"activeCount":8},[],{"trials":3676,"activeCount":8},[],{"intervention":3678,"totalTrials":11,"cells":3679},"bortezomib, rifampicin",{"EARLY_PHASE1":3680,"PHASE1":3682,"PHASE2":3693,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3681,"activeCount":8},[],{"trials":3683,"activeCount":8},[3684],{"nctId":3685,"briefTitle":3686,"status":55,"phases":3687,"primaryCompletion":720,"completion":3688,"start":3689,"enrollment":484,"conditions":3690,"interventions":3691},"NCT00608907","An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)",[39],"2010-04","2007-09",[14,933],[2430,3678,3692],"bortezomib, dexamethasone",{"trials":3694,"activeCount":8},[],{"trials":3696,"activeCount":8},[],{"trials":3698,"activeCount":8},[],{"trials":3700,"activeCount":8},[],{"intervention":3692,"totalTrials":11,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3711,"PHASE3":3713,"PHASE4":3715,"NA":3717},{"trials":3704,"activeCount":8},[],{"trials":3706,"activeCount":8},[3707],{"nctId":3685,"briefTitle":3686,"status":55,"phases":3708,"primaryCompletion":720,"completion":3688,"start":3689,"enrollment":484,"conditions":3709,"interventions":3710},[39],[14,933],[2430,3678,3692],{"trials":3712,"activeCount":8},[],{"trials":3714,"activeCount":8},[],{"trials":3716,"activeCount":8},[],{"trials":3718,"activeCount":8},[],{"intervention":2215,"totalTrials":11,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3729,"PHASE3":3731,"PHASE4":3733,"NA":3735},{"trials":3722,"activeCount":8},[],{"trials":3724,"activeCount":8},[3725],{"nctId":2206,"briefTitle":2207,"status":55,"phases":3726,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":2211,"conditions":3727,"interventions":3728},[39],[20,2213],[2199,1432,2215],{"trials":3730,"activeCount":8},[],{"trials":3732,"activeCount":8},[],{"trials":3734,"activeCount":8},[],{"trials":3736,"activeCount":8},[],{"intervention":3738,"totalTrials":11,"cells":3739},"CT53518",{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3753,"PHASE3":3755,"PHASE4":3757,"NA":3759},{"trials":3741,"activeCount":8},[],{"trials":3743,"activeCount":8},[3744],{"nctId":3745,"briefTitle":3746,"status":55,"phases":3747,"primaryCompletion":3748,"completion":3749,"start":3750,"enrollment":108,"conditions":3751,"interventions":3752},"NCT00064584","Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)",[39],"2005-01","2005-07","2002-05",[28,1995],[3738],{"trials":3754,"activeCount":8},[],{"trials":3756,"activeCount":8},[],{"trials":3758,"activeCount":8},[],{"trials":3760,"activeCount":8},[],{"intervention":2997,"totalTrials":11,"cells":3762},{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3771,"PHASE3":3773,"PHASE4":3775,"NA":3777},{"trials":3764,"activeCount":8},[],{"trials":3766,"activeCount":8},[3767],{"nctId":2987,"briefTitle":2988,"status":55,"phases":3768,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":2993,"conditions":3769,"interventions":3770},[39],[2995,25],[2997,2998,2999,3000,133,3001,2999],{"trials":3772,"activeCount":8},[],{"trials":3774,"activeCount":8},[],{"trials":3776,"activeCount":8},[],{"trials":3778,"activeCount":8},[],{"intervention":2998,"totalTrials":11,"cells":3780},{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3789,"PHASE3":3791,"PHASE4":3793,"NA":3795},{"trials":3782,"activeCount":8},[],{"trials":3784,"activeCount":8},[3785],{"nctId":2987,"briefTitle":2988,"status":55,"phases":3786,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":2993,"conditions":3787,"interventions":3788},[39],[2995,25],[2997,2998,2999,3000,133,3001,2999],{"trials":3790,"activeCount":8},[],{"trials":3792,"activeCount":8},[],{"trials":3794,"activeCount":8},[],{"trials":3796,"activeCount":8},[],{"intervention":2999,"totalTrials":11,"cells":3798},{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3807,"PHASE3":3809,"PHASE4":3811,"NA":3813},{"trials":3800,"activeCount":8},[],{"trials":3802,"activeCount":8},[3803],{"nctId":2987,"briefTitle":2988,"status":55,"phases":3804,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":2993,"conditions":3805,"interventions":3806},[39],[2995,25],[2997,2998,2999,3000,133,3001,2999],{"trials":3808,"activeCount":8},[],{"trials":3810,"activeCount":8},[],{"trials":3812,"activeCount":8},[],{"trials":3814,"activeCount":8},[],{"intervention":3000,"totalTrials":11,"cells":3816},{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3825,"PHASE3":3827,"PHASE4":3829,"NA":3831},{"trials":3818,"activeCount":8},[],{"trials":3820,"activeCount":8},[3821],{"nctId":2987,"briefTitle":2988,"status":55,"phases":3822,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":2993,"conditions":3823,"interventions":3824},[39],[2995,25],[2997,2998,2999,3000,133,3001,2999],{"trials":3826,"activeCount":8},[],{"trials":3828,"activeCount":8},[],{"trials":3830,"activeCount":8},[],{"trials":3832,"activeCount":8},[],{"intervention":3001,"totalTrials":11,"cells":3834},{"EARLY_PHASE1":3835,"PHASE1":3837,"PHASE2":3843,"PHASE3":3845,"PHASE4":3847,"NA":3849},{"trials":3836,"activeCount":8},[],{"trials":3838,"activeCount":8},[3839],{"nctId":2987,"briefTitle":2988,"status":55,"phases":3840,"primaryCompletion":2990,"completion":2991,"start":2992,"enrollment":2993,"conditions":3841,"interventions":3842},[39],[2995,25],[2997,2998,2999,3000,133,3001,2999],{"trials":3844,"activeCount":8},[],{"trials":3846,"activeCount":8},[],{"trials":3848,"activeCount":8},[],{"trials":3850,"activeCount":8},[],{"intervention":3383,"totalTrials":11,"cells":3852},{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3854,"activeCount":8},[],{"trials":3856,"activeCount":8},[3857],{"nctId":3373,"briefTitle":3374,"status":55,"phases":3858,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":3379,"conditions":3859,"interventions":3860},[39],[3381],[3356,3383],{"trials":3862,"activeCount":8},[],{"trials":3864,"activeCount":8},[],{"trials":3866,"activeCount":8},[],{"trials":3868,"activeCount":8},[],{"intervention":1458,"totalTrials":11,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3872,"activeCount":8},[],{"trials":3874,"activeCount":8},[3875],{"nctId":1448,"briefTitle":1449,"status":55,"phases":3876,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":1453,"conditions":3877,"interventions":3878},[39],[1455,396],[285,1457,1458],{"trials":3880,"activeCount":8},[],{"trials":3882,"activeCount":8},[],{"trials":3884,"activeCount":8},[],{"trials":3886,"activeCount":8},[],{"intervention":3888,"totalTrials":11,"cells":3889},"TAK-701",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3901,"PHASE3":3903,"PHASE4":3905,"NA":3907},{"trials":3891,"activeCount":8},[],{"trials":3893,"activeCount":8},[3894],{"nctId":3895,"briefTitle":3896,"status":55,"phases":3897,"primaryCompletion":617,"completion":3898,"start":3307,"enrollment":463,"conditions":3899,"interventions":3900},"NCT00831896","Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies",[39],"2011-05",[17],[3888],{"trials":3902,"activeCount":8},[],{"trials":3904,"activeCount":8},[],{"trials":3906,"activeCount":8},[],{"trials":3908,"activeCount":8},[],{"intervention":3910,"totalTrials":11,"cells":3911},"Pevonedistat 25 mg\u002Fm^2",{"EARLY_PHASE1":3912,"PHASE1":3914,"PHASE2":3928,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3913,"activeCount":8},[],{"trials":3915,"activeCount":8},[3916],{"nctId":3917,"briefTitle":3918,"status":55,"phases":3919,"primaryCompletion":3920,"completion":3920,"start":1725,"enrollment":3921,"conditions":3922,"interventions":3923},"NCT02782468","A Study of Pevonedistat in Adult East Asian Participants",[39],"2022-01-25",23,[1841,1839],[3910,3924,3925,3926,3927],"Pevonedistat 44 mg\u002Fm^2","Pevonedistat 10 mg\u002Fm^2","Pevonedistat 20 mg\u002Fm^2","Azacitidine 75 mg\u002Fm^2",{"trials":3929,"activeCount":8},[],{"trials":3931,"activeCount":8},[],{"trials":3933,"activeCount":8},[],{"trials":3935,"activeCount":8},[],{"intervention":3924,"totalTrials":11,"cells":3937},{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3946,"PHASE3":3948,"PHASE4":3950,"NA":3952},{"trials":3939,"activeCount":8},[],{"trials":3941,"activeCount":8},[3942],{"nctId":3917,"briefTitle":3918,"status":55,"phases":3943,"primaryCompletion":3920,"completion":3920,"start":1725,"enrollment":3921,"conditions":3944,"interventions":3945},[39],[1841,1839],[3910,3924,3925,3926,3927],{"trials":3947,"activeCount":8},[],{"trials":3949,"activeCount":8},[],{"trials":3951,"activeCount":8},[],{"trials":3953,"activeCount":8},[],{"intervention":3925,"totalTrials":11,"cells":3955},{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3964,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3957,"activeCount":8},[],{"trials":3959,"activeCount":8},[3960],{"nctId":3917,"briefTitle":3918,"status":55,"phases":3961,"primaryCompletion":3920,"completion":3920,"start":1725,"enrollment":3921,"conditions":3962,"interventions":3963},[39],[1841,1839],[3910,3924,3925,3926,3927],{"trials":3965,"activeCount":8},[],{"trials":3967,"activeCount":8},[],{"trials":3969,"activeCount":8},[],{"trials":3971,"activeCount":8},[],{"intervention":3926,"totalTrials":11,"cells":3973},{"EARLY_PHASE1":3974,"PHASE1":3976,"PHASE2":3982,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3975,"activeCount":8},[],{"trials":3977,"activeCount":8},[3978],{"nctId":3917,"briefTitle":3918,"status":55,"phases":3979,"primaryCompletion":3920,"completion":3920,"start":1725,"enrollment":3921,"conditions":3980,"interventions":3981},[39],[1841,1839],[3910,3924,3925,3926,3927],{"trials":3983,"activeCount":8},[],{"trials":3985,"activeCount":8},[],{"trials":3987,"activeCount":8},[],{"trials":3989,"activeCount":8},[],{"intervention":3927,"totalTrials":11,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":4000,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3993,"activeCount":8},[],{"trials":3995,"activeCount":8},[3996],{"nctId":3917,"briefTitle":3918,"status":55,"phases":3997,"primaryCompletion":3920,"completion":3920,"start":1725,"enrollment":3921,"conditions":3998,"interventions":3999},[39],[1841,1839],[3910,3924,3925,3926,3927],{"trials":4001,"activeCount":8},[],{"trials":4003,"activeCount":8},[],{"trials":4005,"activeCount":8},[],{"trials":4007,"activeCount":8},[],{"intervention":3154,"totalTrials":11,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4011,"activeCount":8},[],{"trials":4013,"activeCount":8},[4014],{"nctId":3146,"briefTitle":3147,"status":55,"phases":4015,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":29,"conditions":4016,"interventions":4017},[39],[23],[3153,3154,3155],{"trials":4019,"activeCount":8},[],{"trials":4021,"activeCount":8},[],{"trials":4023,"activeCount":8},[],{"trials":4025,"activeCount":8},[],{"intervention":3155,"totalTrials":11,"cells":4027},{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4029,"activeCount":8},[],{"trials":4031,"activeCount":8},[4032],{"nctId":3146,"briefTitle":3147,"status":55,"phases":4033,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":29,"conditions":4034,"interventions":4035},[39],[23],[3153,3154,3155],{"trials":4037,"activeCount":8},[],{"trials":4039,"activeCount":8},[],{"trials":4041,"activeCount":8},[],{"trials":4043,"activeCount":8},[],{"intervention":4045,"totalTrials":11,"cells":4046},"[68Ga]MLN6907",{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4059,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4048,"activeCount":8},[],{"trials":4050,"activeCount":8},[4051],{"nctId":4052,"briefTitle":4053,"status":55,"phases":4054,"primaryCompletion":4055,"completion":4055,"start":58,"enrollment":60,"conditions":4056,"interventions":4058},"NCT02056015","A Phase I Study of MLN6907 in Patients With Metastatic Colorectal",[39],"2015-09",[4057],"Imaging of Solid Gastrointestinal Tumors",[4045],{"trials":4060,"activeCount":8},[],{"trials":4062,"activeCount":8},[],{"trials":4064,"activeCount":8},[],{"trials":4066,"activeCount":8},[],{"intervention":4068,"totalTrials":11,"cells":4069},"Tandutinib, bevacizumab, and temozolomide",{"EARLY_PHASE1":4070,"PHASE1":4072,"PHASE2":4082,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4071,"activeCount":8},[],{"trials":4073,"activeCount":8},[4074],{"nctId":4075,"briefTitle":4076,"status":431,"phases":4077,"primaryCompletion":918,"completion":929,"start":1992,"enrollment":4078,"conditions":4079,"interventions":4081},"NCT00904852","Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme",[39],30,[4080],"Glioblastoma Multiforme",[4068],{"trials":4083,"activeCount":8},[],{"trials":4085,"activeCount":8},[],{"trials":4087,"activeCount":8},[],{"trials":4089,"activeCount":8},[],{"intervention":4091,"totalTrials":11,"cells":4092},"TAK-079",{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4108,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4094,"activeCount":8},[],{"trials":4096,"activeCount":8},[4097],{"nctId":4098,"briefTitle":4099,"status":55,"phases":4100,"primaryCompletion":4101,"completion":4101,"start":4102,"enrollment":3921,"conditions":4103,"interventions":4106},"NCT03724916","A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)",[39],"2021-11-04","2018-11-26",[4104,4105],"Systemic Lupus Erythematosus","Lupus Erythematosus, Systemic",[4091,4107],"TAK-079 Placebo",{"trials":4109,"activeCount":8},[],{"trials":4111,"activeCount":8},[],{"trials":4113,"activeCount":8},[],{"trials":4115,"activeCount":8},[],{"intervention":4107,"totalTrials":11,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4126,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4119,"activeCount":8},[],{"trials":4121,"activeCount":8},[4122],{"nctId":4098,"briefTitle":4099,"status":55,"phases":4123,"primaryCompletion":4101,"completion":4101,"start":4102,"enrollment":3921,"conditions":4124,"interventions":4125},[39],[4104,4105],[4091,4107],{"trials":4127,"activeCount":8},[],{"trials":4129,"activeCount":8},[],{"trials":4131,"activeCount":8},[],{"trials":4133,"activeCount":8},[],{"intervention":4135,"totalTrials":11,"cells":4136},"TAK-593",{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4147,"PHASE3":4149,"PHASE4":4151,"NA":4153},{"trials":4138,"activeCount":8},[],{"trials":4140,"activeCount":8},[4141],{"nctId":4142,"briefTitle":4143,"status":55,"phases":4144,"primaryCompletion":785,"completion":3688,"start":755,"enrollment":108,"conditions":4145,"interventions":4146},"NCT00773929","Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer",[39],[130],[4135],{"trials":4148,"activeCount":8},[],{"trials":4150,"activeCount":8},[],{"trials":4152,"activeCount":8},[],{"trials":4154,"activeCount":8},[],{"intervention":1478,"totalTrials":11,"cells":4156},{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4165,"PHASE3":4167,"PHASE4":4169,"NA":4171},{"trials":4158,"activeCount":8},[],{"trials":4160,"activeCount":8},[4161],{"nctId":1468,"briefTitle":1469,"status":55,"phases":4162,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":26,"conditions":4163,"interventions":4164},[39],[1475],[1477,1478,165,1061,179],{"trials":4166,"activeCount":8},[],{"trials":4168,"activeCount":8},[],{"trials":4170,"activeCount":8},[],{"trials":4172,"activeCount":8},[],{"intervention":1732,"totalTrials":11,"cells":4174},{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4183,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4176,"activeCount":8},[],{"trials":4178,"activeCount":8},[4179],{"nctId":1722,"briefTitle":1723,"status":55,"phases":4180,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":1728,"conditions":4181,"interventions":4182},[39],[1730],[1575,1732,1575],{"trials":4184,"activeCount":8},[],{"trials":4186,"activeCount":8},[],{"trials":4188,"activeCount":8},[],{"trials":4190,"activeCount":8},[],{"intervention":4192,"totalTrials":11,"cells":4193},"TAK-733",{"EARLY_PHASE1":4194,"PHASE1":4196,"PHASE2":4207,"PHASE3":4209,"PHASE4":4211,"NA":4213},{"trials":4195,"activeCount":8},[],{"trials":4197,"activeCount":8},[4198],{"nctId":4199,"briefTitle":4200,"status":55,"phases":4201,"primaryCompletion":4202,"completion":4203,"start":2930,"enrollment":1429,"conditions":4204,"interventions":4206},"NCT00948467","Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies",[39],"2013-04","2013-06",[414,4205],"Advanced Metastatic Melanoma",[4192],{"trials":4208,"activeCount":8},[],{"trials":4210,"activeCount":8},[],{"trials":4212,"activeCount":8},[],{"trials":4214,"activeCount":8},[],{"intervention":4216,"totalTrials":11,"cells":4217},"TAK-733 and alisertib",{"EARLY_PHASE1":4218,"PHASE1":4220,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4219,"activeCount":8},[],{"trials":4221,"activeCount":8},[4222],{"nctId":4223,"briefTitle":4224,"status":431,"phases":4225,"primaryCompletion":4055,"completion":4226,"start":394,"enrollment":8,"conditions":4227,"interventions":4228},"NCT01613261","Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies",[39],"2015-11",[31],[4216],{"trials":4230,"activeCount":8},[],{"trials":4232,"activeCount":8},[],{"trials":4234,"activeCount":8},[],{"trials":4236,"activeCount":8},[],{"intervention":4238,"totalTrials":11,"cells":4239},"TAK-960",{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4251,"PHASE3":4253,"PHASE4":4255,"NA":4257},{"trials":4241,"activeCount":8},[],{"trials":4243,"activeCount":8},[4244],{"nctId":4245,"briefTitle":4246,"status":169,"phases":4247,"primaryCompletion":4248,"completion":820,"start":1197,"enrollment":173,"conditions":4249,"interventions":4250},"NCT01179399","Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies",[39],"2012-10",[2489],[4238],{"trials":4252,"activeCount":8},[],{"trials":4254,"activeCount":8},[],{"trials":4256,"activeCount":8},[],{"trials":4258,"activeCount":8},[],{"intervention":691,"totalTrials":11,"cells":4260},{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4269,"PHASE3":4271,"PHASE4":4273,"NA":4275},{"trials":4262,"activeCount":8},[],{"trials":4264,"activeCount":8},[4265],{"nctId":680,"briefTitle":681,"status":55,"phases":4266,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":4267,"interventions":4268},[39],[688],[690,691,692],{"trials":4270,"activeCount":8},[],{"trials":4272,"activeCount":8},[],{"trials":4274,"activeCount":8},[],{"trials":4276,"activeCount":8},[],{"intervention":692,"totalTrials":11,"cells":4278},{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4287,"PHASE3":4289,"PHASE4":4291,"NA":4293},{"trials":4280,"activeCount":8},[],{"trials":4282,"activeCount":8},[4283],{"nctId":680,"briefTitle":681,"status":55,"phases":4284,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":4285,"interventions":4286},[39],[688],[690,691,692],{"trials":4288,"activeCount":8},[],{"trials":4290,"activeCount":8},[],{"trials":4292,"activeCount":8},[],{"trials":4294,"activeCount":8},[],{"intervention":2337,"totalTrials":11,"cells":4296},{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4311},{"trials":4298,"activeCount":8},[],{"trials":4300,"activeCount":8},[4301],{"nctId":2330,"briefTitle":2331,"status":55,"phases":4302,"primaryCompletion":2333,"completion":2333,"start":2334,"enrollment":29,"conditions":4303,"interventions":4304},[39],[23],[2323,2337],{"trials":4306,"activeCount":8},[],{"trials":4308,"activeCount":8},[],{"trials":4310,"activeCount":8},[],{"trials":4312,"activeCount":8},[],{"intervention":66,"totalTrials":11,"cells":4314},{"EARLY_PHASE1":4315,"PHASE1":4317,"PHASE2":4323,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4316,"activeCount":8},[],{"trials":4318,"activeCount":8},[4319],{"nctId":53,"briefTitle":54,"status":55,"phases":4320,"primaryCompletion":57,"completion":58,"start":59,"enrollment":60,"conditions":4321,"interventions":4322},[39],[62,63],[65,66],{"trials":4324,"activeCount":8},[],{"trials":4326,"activeCount":8},[],{"trials":4328,"activeCount":8},[],{"trials":4330,"activeCount":8},[],{"intervention":4332,"totalTrials":11,"cells":4333},"[14C]-TAK-954",{"EARLY_PHASE1":4334,"PHASE1":4336,"PHASE2":4345,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4335,"activeCount":8},[],{"trials":4337,"activeCount":8},[4338],{"nctId":4339,"briefTitle":4340,"status":55,"phases":4341,"primaryCompletion":4342,"completion":4342,"start":1715,"enrollment":29,"conditions":4343,"interventions":4344},"NCT03500224","A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants",[39],"2018-06-01",[23],[4332],{"trials":4346,"activeCount":8},[],{"trials":4348,"activeCount":8},[],{"trials":4350,"activeCount":8},[],{"trials":4352,"activeCount":8},[],{"intervention":4354,"totalTrials":11,"cells":4355},"PvP001 100 mg",{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4380,"PHASE3":4382,"PHASE4":4384,"NA":4386},{"trials":4357,"activeCount":8},[],{"trials":4359,"activeCount":8},[4360],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4363,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4368,"interventions":4370},"NCT03701555","A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease",[39],"2021-01-31","2021-07-02","2018-06-19",139,[4369],"Digestive System Disease",[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],"PvP001 300 mg","PvP001 900 mg","Maximum Feasible Dose (MFD) of PvP002","Maximum Tolerated Dose (MTD) of PvP001","MTD of PvP001 following 7 days of PPI treatment","PvP001 600 mg","PvP003 placebo","PvP003","PvP003 150 mg",{"trials":4381,"activeCount":8},[],{"trials":4383,"activeCount":8},[],{"trials":4385,"activeCount":8},[],{"trials":4387,"activeCount":8},[],{"intervention":4371,"totalTrials":11,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4398,"PHASE3":4400,"PHASE4":4402,"NA":4404},{"trials":4391,"activeCount":8},[],{"trials":4393,"activeCount":8},[4394],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4395,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4396,"interventions":4397},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4399,"activeCount":8},[],{"trials":4401,"activeCount":8},[],{"trials":4403,"activeCount":8},[],{"trials":4405,"activeCount":8},[],{"intervention":4372,"totalTrials":11,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4416,"PHASE3":4418,"PHASE4":4420,"NA":4422},{"trials":4409,"activeCount":8},[],{"trials":4411,"activeCount":8},[4412],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4413,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4414,"interventions":4415},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4417,"activeCount":8},[],{"trials":4419,"activeCount":8},[],{"trials":4421,"activeCount":8},[],{"trials":4423,"activeCount":8},[],{"intervention":4373,"totalTrials":11,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4434,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4427,"activeCount":8},[],{"trials":4429,"activeCount":8},[4430],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4431,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4432,"interventions":4433},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4435,"activeCount":8},[],{"trials":4437,"activeCount":8},[],{"trials":4439,"activeCount":8},[],{"trials":4441,"activeCount":8},[],{"intervention":4374,"totalTrials":11,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4452,"PHASE3":4454,"PHASE4":4456,"NA":4458},{"trials":4445,"activeCount":8},[],{"trials":4447,"activeCount":8},[4448],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4449,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4450,"interventions":4451},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4453,"activeCount":8},[],{"trials":4455,"activeCount":8},[],{"trials":4457,"activeCount":8},[],{"trials":4459,"activeCount":8},[],{"intervention":4375,"totalTrials":11,"cells":4461},{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4470,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4463,"activeCount":8},[],{"trials":4465,"activeCount":8},[4466],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4467,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4468,"interventions":4469},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4471,"activeCount":8},[],{"trials":4473,"activeCount":8},[],{"trials":4475,"activeCount":8},[],{"trials":4477,"activeCount":8},[],{"intervention":4376,"totalTrials":11,"cells":4479},{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4488,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4481,"activeCount":8},[],{"trials":4483,"activeCount":8},[4484],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4485,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4486,"interventions":4487},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4489,"activeCount":8},[],{"trials":4491,"activeCount":8},[],{"trials":4493,"activeCount":8},[],{"trials":4495,"activeCount":8},[],{"intervention":4377,"totalTrials":11,"cells":4497},{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4506,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4499,"activeCount":8},[],{"trials":4501,"activeCount":8},[4502],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4503,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4504,"interventions":4505},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4507,"activeCount":8},[],{"trials":4509,"activeCount":8},[],{"trials":4511,"activeCount":8},[],{"trials":4513,"activeCount":8},[],{"intervention":4378,"totalTrials":11,"cells":4515},{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4517,"activeCount":8},[],{"trials":4519,"activeCount":8},[4520],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4521,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4522,"interventions":4523},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4525,"activeCount":8},[],{"trials":4527,"activeCount":8},[],{"trials":4529,"activeCount":8},[],{"trials":4531,"activeCount":8},[],{"intervention":4379,"totalTrials":11,"cells":4533},{"EARLY_PHASE1":4534,"PHASE1":4536,"PHASE2":4542,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4535,"activeCount":8},[],{"trials":4537,"activeCount":8},[4538],{"nctId":4361,"briefTitle":4362,"status":55,"phases":4539,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4540,"interventions":4541},[39],[4369],[4354,4371,4372,4373,4374,4375,4376,4377,4378,4379],{"trials":4543,"activeCount":8},[],{"trials":4545,"activeCount":8},[],{"trials":4547,"activeCount":8},[],{"trials":4549,"activeCount":8},[],{"intervention":242,"totalTrials":11,"cells":4551},{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4560,"PHASE3":4562,"PHASE4":4564,"NA":4566},{"trials":4553,"activeCount":8},[],{"trials":4555,"activeCount":8},[4556],{"nctId":233,"briefTitle":234,"status":55,"phases":4557,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":4558,"interventions":4559},[39],[17,25],[242,211],{"trials":4561,"activeCount":8},[],{"trials":4563,"activeCount":8},[],{"trials":4565,"activeCount":8},[],{"trials":4567,"activeCount":8},[],{"intervention":3188,"totalTrials":11,"cells":4569},{"EARLY_PHASE1":4570,"PHASE1":4572,"PHASE2":4578,"PHASE3":4580,"PHASE4":4582,"NA":4584},{"trials":4571,"activeCount":8},[],{"trials":4573,"activeCount":8},[4574],{"nctId":3179,"briefTitle":3180,"status":55,"phases":4575,"primaryCompletion":3182,"completion":3183,"start":3184,"enrollment":141,"conditions":4576,"interventions":4577},[39],[1640,3186],[3188,3020],{"trials":4579,"activeCount":8},[],{"trials":4581,"activeCount":8},[],{"trials":4583,"activeCount":8},[],{"trials":4585,"activeCount":8},[],{"intervention":4587,"totalTrials":11,"cells":4588},"MLN518",{"EARLY_PHASE1":4589,"PHASE1":4591,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4590,"activeCount":8},[],{"trials":4592,"activeCount":8},[4593],{"nctId":4594,"briefTitle":4595,"status":55,"phases":4596,"primaryCompletion":701,"start":4597,"conditions":4598,"interventions":4599},"NCT00274248","MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia",[39],"2005-03",[28],[4587],{"trials":4601,"activeCount":8},[],{"trials":4603,"activeCount":8},[],{"trials":4605,"activeCount":8},[],{"trials":4607,"activeCount":8},[],{"intervention":2069,"totalTrials":11,"cells":4609},{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4618,"PHASE3":4620,"PHASE4":4622,"NA":4624},{"trials":4611,"activeCount":8},[],{"trials":4613,"activeCount":8},[4614],{"nctId":2061,"briefTitle":2062,"status":55,"phases":4615,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":60,"conditions":4616,"interventions":4617},[39],[2067],[2069,2045,132],{"trials":4619,"activeCount":8},[],{"trials":4621,"activeCount":8},[],{"trials":4623,"activeCount":8},[],{"trials":4625,"activeCount":8},[],{"intervention":286,"totalTrials":11,"cells":4627},{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4636,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4629,"activeCount":8},[],{"trials":4631,"activeCount":8},[4632],{"nctId":276,"briefTitle":277,"status":55,"phases":4633,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":4634,"interventions":4635},[39],[31],[284,285,114,179,286,287],{"trials":4637,"activeCount":8},[],{"trials":4639,"activeCount":8},[],{"trials":4641,"activeCount":8},[],{"trials":4643,"activeCount":8},[],{"intervention":287,"totalTrials":11,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4647,"activeCount":8},[],{"trials":4649,"activeCount":8},[4650],{"nctId":276,"briefTitle":277,"status":55,"phases":4651,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":4652,"interventions":4653},[39],[31],[284,285,114,179,286,287],{"trials":4655,"activeCount":8},[],{"trials":4657,"activeCount":8},[],{"trials":4659,"activeCount":8},[],{"trials":4661,"activeCount":8},[],{"intervention":4663,"totalTrials":11,"cells":4664},"TAK-418",{"EARLY_PHASE1":4665,"PHASE1":4667,"PHASE2":4677,"PHASE3":4679,"PHASE4":4681,"NA":4683},{"trials":4666,"activeCount":8},[],{"trials":4668,"activeCount":8},[4669],{"nctId":4670,"briefTitle":4671,"status":169,"phases":4672,"primaryCompletion":4673,"completion":4673,"start":4674,"enrollment":173,"conditions":4675,"interventions":4676},"NCT03501069","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants",[39],"2018-12-26","2018-05-30",[23],[4663],{"trials":4678,"activeCount":8},[],{"trials":4680,"activeCount":8},[],{"trials":4682,"activeCount":8},[],{"trials":4684,"activeCount":8},[],{"intervention":2430,"totalTrials":21,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4708,"PHASE3":4718,"PHASE4":4746,"NA":4755},{"trials":4688,"activeCount":8},[],{"trials":4690,"activeCount":8},[4691,4698,4702],{"nctId":4692,"briefTitle":4693,"status":55,"phases":4694,"primaryCompletion":4695,"conditions":4696,"interventions":4697},"NCT00129207","Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade",[39],"2006-09",[3422],[2430],{"nctId":3685,"briefTitle":3686,"status":55,"phases":4699,"primaryCompletion":720,"completion":3688,"start":3689,"enrollment":484,"conditions":4700,"interventions":4701},[39],[14,933],[2430,3678,3692],{"nctId":4703,"briefTitle":4704,"status":55,"phases":4705,"primaryCompletion":1599,"start":2380,"enrollment":2211,"conditions":4706,"interventions":4707},"NCT00080405","Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma",[39],[14],[649],{"trials":4709,"activeCount":8},[4710,4714],{"nctId":2423,"briefTitle":2424,"status":431,"phases":4711,"primaryCompletion":901,"start":2426,"enrollment":2427,"conditions":4712,"interventions":4713},[40],[197],[2430,2414],{"nctId":791,"briefTitle":792,"status":55,"phases":4715,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":4716,"interventions":4717},[40],[798],[649,335,540,789,336,488],{"trials":4719,"activeCount":8},[4720,4724,4730,4738],{"nctId":641,"briefTitle":642,"status":55,"phases":4721,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":4722,"interventions":4723},[41],[14],[649,427,487,488,553],{"nctId":4725,"briefTitle":4726,"status":55,"phases":4727,"primaryCompletion":1637,"start":2103,"conditions":4728,"interventions":4729},"NCT00111319","VELCADE\u002FMelphalan\u002FPrednisone Versus Melphalan\u002FPrednisone in Patients With Previously Untreated Multiple Myeloma",[41],[14],[2430],{"nctId":4731,"briefTitle":4732,"status":55,"phases":4733,"primaryCompletion":2279,"completion":3749,"start":4734,"enrollment":4735,"conditions":4736,"interventions":4737},"NCT00063726","A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039",[41],"2002-04",600,[14],[2430],{"nctId":4739,"briefTitle":4740,"status":55,"phases":4741,"primaryCompletion":4742,"completion":2103,"start":2669,"enrollment":4743,"conditions":4744,"interventions":4745},"NCT00048230","PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",[41],"2004-07",620,[14],[2430],{"trials":4747,"activeCount":8},[4748],{"nctId":4749,"briefTitle":4750,"status":55,"phases":4751,"primaryCompletion":4752,"conditions":4753,"interventions":4754},"NCT00257114","Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability",[42],"2007-03",[14],[2430],{"trials":4756,"activeCount":8},[4757],{"nctId":4758,"briefTitle":4759,"status":4760,"phases":4761,"conditions":4762,"interventions":4763},"NCT00063791","A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE","NO_LONGER_AVAILABLE",[],[14],[649],{"intervention":4765,"totalTrials":1101,"cells":4766},"Mifamurtide",{"EARLY_PHASE1":4767,"PHASE1":4769,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4768,"activeCount":8},[],{"trials":4770,"activeCount":8},[],{"trials":4772,"activeCount":8},[],{"trials":4774,"activeCount":8},[],{"trials":4776,"activeCount":8},[],{"trials":4778,"activeCount":8},[4779,4787],{"nctId":4780,"briefTitle":4781,"status":169,"phases":4782,"primaryCompletion":4783,"completion":4783,"start":753,"enrollment":3368,"conditions":4784,"interventions":4786},"NCT01194284","Surveillance Study of Patients With Newly Diagnosed Osteosarcoma",[],"2013-12",[4785],"Osteosarcoma",[4765],{"nctId":4788,"briefTitle":4789,"status":55,"phases":4790,"primaryCompletion":4248,"completion":4248,"start":3262,"enrollment":4791,"conditions":4792,"interventions":4793},"NCT00631631","Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma",[],205,[4785],[4765],{"intervention":4795,"totalTrials":11,"cells":4796},"Mobocertinib 160 mg",{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4801,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4798,"activeCount":8},[],{"trials":4800,"activeCount":8},[],{"trials":4802,"activeCount":8},[],{"trials":4804,"activeCount":8},[],{"trials":4806,"activeCount":8},[],{"trials":4808,"activeCount":8},[4809],{"nctId":4810,"briefTitle":4811,"status":4812,"phases":4813,"conditions":4814,"interventions":4815},"NCT04535557","An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations","APPROVED_FOR_MARKETING",[],[1640],[4795]]